{"meta":{"page":1,"per_page":50,"max_per_page":100,"total":2464,"total_is_capped":false,"direct_labels_cover":16,"predictions_cover":2464,"direct_label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline (scores rank; they never assert a category)","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"query_hash":"f6b61b014da0","filters":{"topic":"Lung Cancer Treatments and Mutations"}},"results":[{"id":"W2180481128","doi":"10.1038/nature13385","title":"Comprehensive molecular profiling of lung adenocarcinoma","year":2014,"lang":"en","type":"article","venue":"Nature","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5830,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ontario Institute for Cancer Research; BC Cancer Agency; Princess Margaret Cancer Centre","funders":"National Center for Advancing Translational Sciences; National Institute of General Medical Sciences; National Cancer Institute; National Institutes of Health; National Human Genome Research Institute; Howard Hughes Medical Institute","keywords":"Biology; Exon; Adenocarcinoma; Somatic cell; Alternative splicing; Lung cancer; KRAS; RNA splicing; Cancer research; Germline mutation; Messenger RNA; Genetics; Gene; Oncogene; Mutation; Molecular biology; Cancer; RNA; Medicine; Pathology; Cell cycle","retraction":null,"screen_n_in":null,"score":{"opus":0.006625504655281512,"gpt":0.3152565461208155,"spread":0.308631041465534,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00001734622,0.00005880225,0.0001268731,0.00003752791,0.00001929926,0.000002578749,0.00002948829,0.0002319233,0.0000208262],"category_scores_gemma":[0.0000243228,0.00004479212,0.00004882303,0.00008308193,0.00001808163,0.0000171184,0.00001014477,0.0003635655,0.000003921993],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002846199,"about_ca_system_score_gemma":0.00004166771,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000006908698,"about_ca_topic_score_gemma":3.488597e-7,"domain_scores_codex":[0.9996077,0.00001154289,0.00007617744,0.0001039262,0.0001226098,0.00007805738],"domain_scores_gemma":[0.9996315,0.00001986735,0.00003360381,0.000144958,0.0001295948,0.00004042708],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0003472155,0.0005261995,0.588376,0.001873955,0.001495131,0.000197146,0.001692098,0.0002009146,0.3245417,0.05950947,0.009115962,0.01212428],"study_design_scores_gemma":[0.007229827,0.0007467841,0.5377171,0.0004489138,0.0015101,0.0001227622,0.0002891052,0.002849261,0.4136966,0.001215428,0.03384126,0.0003328544],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9815511,0.00647372,0.0003928403,0.0009381677,0.0001486563,0.0002998948,0.000009047898,0.00002941023,0.01015721],"genre_scores_gemma":[0.9953005,0.000005332212,0.003365563,0.001002461,0.000057573,0.000007593585,0.0000422199,0.000009546882,0.0002091652],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.08915495,"threshold_uncertainty_score":0.1826569,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2138297714","doi":"10.1056/nejmoa050753","title":"Erlotinib in Previously Treated Non–Small-Cell Lung Cancer","year":2005,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":5451,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ontario Institute for Cancer Research; Hotel Dieu Shaver Health and Rehabilitation Centre; Princess Margaret Cancer Centre; University Health Network; University of Toronto; McGill University","funders":"National Cancer Institute","keywords":"Erlotinib; Medicine; Lung cancer; Hazard ratio; Internal medicine; Erlotinib Hydrochloride; Chemotherapy; Randomization; Placebo; Performance status; Oncology; Surgery; Epidermal growth factor receptor; Gastroenterology; Cancer; Randomized controlled trial; Confidence interval; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.0143240950170995,"gpt":0.3292720035477968,"spread":0.3149479085306973,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003205199,0.000152865,0.0004871678,0.000249441,0.00002832516,0.00000582427,0.00007685786,0.00005766295,0.000611259],"category_scores_gemma":[0.00006746814,0.00009287093,0.0000672551,0.0002341144,0.0000326378,0.00008057413,0.000007932216,0.0002845899,0.000004648884],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002742593,"about_ca_system_score_gemma":0.000509307,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008503137,"about_ca_topic_score_gemma":0.000737317,"domain_scores_codex":[0.9987895,0.00003592957,0.0005432405,0.000124608,0.0002789742,0.0002277874],"domain_scores_gemma":[0.9990606,0.00008234906,0.0002481028,0.0001274581,0.0001548121,0.0003266916],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.001313531,0.0005644912,0.5322969,0.0001970101,0.000477807,0.0008718219,0.01105291,0.0006414033,0.004474779,0.00002120555,0.03978077,0.4083073],"study_design_scores_gemma":[0.4522726,0.005619603,0.2379692,0.006142143,0.005124988,0.002344217,0.0008528337,0.001321733,0.004309927,0.00007606537,0.2835312,0.0004355007],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9609581,0.01298261,0.0001676345,0.01758846,0.0003386611,0.0004407687,0.000002341187,0.00001241477,0.007508975],"genre_scores_gemma":[0.9853162,0.002410377,0.0008931273,0.001042188,0.004367189,0.000008697659,0.00000843373,0.00002227689,0.005931521],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4509591,"threshold_uncertainty_score":0.6692857,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2002937040","doi":"10.1371/journal.pmed.0020073","title":"Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain","year":2005,"lang":"en","type":"article","venue":"PLoS Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3526,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; Washington University in St. Louis; Genentech; AstraZeneca; LUNGevity Foundation; Memorial Sloan-Kettering Cancer Center; CHEST Foundation; Canadian Institutes of Health Research; American Cancer Society","keywords":"Gefitinib; Erlotinib; T790M; Cancer research; Epidermal growth factor receptor; Lung cancer; Resistance mutation; Medicine; Mutation; Erlotinib Hydrochloride; Tyrosine kinase; Tyrosine-kinase inhibitor; Biology; Cancer; Oncology; Internal medicine; Genetics; Receptor","retraction":null,"screen_n_in":null,"score":{"opus":0.02397308457094872,"gpt":0.3131054173142422,"spread":0.2891323327432935,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002936707,0.0001754166,0.0004212134,0.0001809564,0.00006460841,0.000006603467,0.0001091091,0.00006091959,0.0008662339],"category_scores_gemma":[0.0003778964,0.00009342835,0.00003400177,0.0007014674,0.0001060934,0.00007956972,0.00001117433,0.0001039075,0.000009043301],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002724385,"about_ca_system_score_gemma":0.0001865157,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00006790461,"about_ca_topic_score_gemma":0.002685407,"domain_scores_codex":[0.9984471,0.00008083708,0.0004205908,0.0002688788,0.0005266306,0.0002559206],"domain_scores_gemma":[0.9988384,0.0003800197,0.0001742898,0.0003136584,0.0001737057,0.0001198882],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"qualitative","study_design_gemma":"observational","study_design_scores_codex":[0.01579305,0.007229642,0.1525727,0.001941824,0.003747236,0.004760139,0.6095864,0.00006204801,0.03232706,0.003724256,0.1595258,0.00872991],"study_design_scores_gemma":[0.04788715,0.004904659,0.8821416,0.008275422,0.002927337,0.0001990991,0.02403618,0.0002830029,0.01118207,0.0004763174,0.01706127,0.0006258186],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9678253,0.0007718156,0.00004353161,0.02361602,0.00003764166,0.00126194,0.0000672887,0.00003325608,0.006343189],"genre_scores_gemma":[0.990626,0.00001303413,0.0009643787,0.004817464,0.0001957273,0.0001675889,0.0001294333,0.00002639205,0.003059945],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.729569,"threshold_uncertainty_score":0.9484653,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2560717039","doi":"10.1056/nejmoa1612674","title":"Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer","year":2016,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3329,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Cancer Research UK","keywords":"Osimertinib; T790M; Pemetrexed; Lung cancer; Medicine; Epidermal growth factor receptor; Oncology; Tyrosine-kinase inhibitor; Tyrosine kinase; Internal medicine; Cancer research; Chemotherapy; Cancer; Receptor; Erlotinib; Gefitinib; Cisplatin","retraction":null,"screen_n_in":null,"score":{"opus":0.01813295790068458,"gpt":0.3557524786313276,"spread":0.3376195207306431,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003458695,0.0001625616,0.0005271108,0.0002695455,0.00003208683,0.000004120427,0.00007980478,0.00005827309,0.001373556],"category_scores_gemma":[0.0004015765,0.00007047223,0.00006545382,0.0002903115,0.00007155308,0.0001312775,0.00001222295,0.0001957193,0.000004289887],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003143498,"about_ca_system_score_gemma":0.0006058455,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005510485,"about_ca_topic_score_gemma":0.0003352406,"domain_scores_codex":[0.998571,0.0000569812,0.000578792,0.0001448008,0.0004164285,0.000232033],"domain_scores_gemma":[0.9986253,0.0004138005,0.0003050477,0.000127892,0.0002101955,0.0003177853],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.005271722,0.0002866499,0.2577935,0.00006986428,0.0008130163,0.001625228,0.004251634,0.00001495733,0.01455559,0.00009059196,0.04160612,0.6736212],"study_design_scores_gemma":[0.4928963,0.006750896,0.3969957,0.01432655,0.00289847,0.002700588,0.0006952258,0.00007177802,0.008737289,0.0004485371,0.07306392,0.0004146806],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8968509,0.0125739,0.001871038,0.0798701,0.001597418,0.0006332621,0.00003439573,0.00002841675,0.00654059],"genre_scores_gemma":[0.9883536,0.00188374,0.0004704375,0.001387522,0.003195396,0.000007491206,0.000005171235,0.00002334367,0.004673317],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6732065,"threshold_uncertainty_score":0.9995393,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2990041408","doi":"10.1056/nejmoa1913662","title":"Overall Survival with Osimertinib in Untreated, <i>EGFR</i> -Mutated Advanced NSCLC","year":2019,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2816,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"William Osler Health System; University of Toronto","funders":"AstraZeneca","keywords":"Osimertinib; T790M; Medicine; Oncology; Epidermal growth factor receptor; Lung cancer; Gefitinib; Internal medicine; Hazard ratio; Progression-free survival; Tyrosine kinase; Cancer research; Overall survival; Cancer; Erlotinib; Receptor; Confidence interval","retraction":null,"screen_n_in":null,"score":{"opus":0.008928424385361516,"gpt":0.2917111297997033,"spread":0.2827827054143418,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002782661,0.00017452,0.000596835,0.0002168163,0.0000202284,0.000006127329,0.00007214168,0.00004936562,0.0004622785],"category_scores_gemma":[0.00007622492,0.00009605549,0.00004927801,0.0002711653,0.00004506487,0.0001312618,0.000007844204,0.0002986565,0.00001528159],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001449511,"about_ca_system_score_gemma":0.0003888112,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00035082,"about_ca_topic_score_gemma":0.0001235757,"domain_scores_codex":[0.9986443,0.00005126074,0.0004713932,0.0001527095,0.0004547254,0.0002255929],"domain_scores_gemma":[0.9989546,0.0001468604,0.0002605847,0.0001666211,0.000198802,0.0002725426],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.02609097,0.0007402145,0.6838128,0.0001800889,0.001437984,0.003780147,0.006085542,0.001989943,0.02281367,0.0004291322,0.005603729,0.2470358],"study_design_scores_gemma":[0.6468135,0.01603597,0.2359904,0.004459331,0.001423218,0.003430001,0.001274345,0.0001484283,0.00161172,0.0003827568,0.08805318,0.0003772296],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9760741,0.001337043,0.0001208764,0.008110547,0.000532159,0.0003365223,0.000002578742,0.0000159075,0.01347026],"genre_scores_gemma":[0.9952014,0.000274237,0.0004997579,0.0007687793,0.000705462,0.000001897106,0.00002201325,0.00002476958,0.002501672],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6207225,"threshold_uncertainty_score":0.5061625,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2134667653","doi":"10.1200/jco.2004.08.163","title":"Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2433,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Docetaxel; Pemetrexed; Neutropenia; Internal medicine; Lung cancer; Febrile neutropenia; Chemotherapy; Regimen; Dexamethasone; Chemotherapy regimen; Gastroenterology; Phases of clinical research; Oncology; Surgery; Cisplatin","retraction":null,"screen_n_in":null,"score":{"opus":0.04615425508884495,"gpt":0.4591494644487017,"spread":0.4129952093598567,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001051495,0.0001794287,0.002421539,0.0001696853,0.00002284824,0.000005158924,0.00009388992,0.0001897106,0.0000915265],"category_scores_gemma":[0.0003426865,0.00009518034,0.0003518582,0.0002582961,0.0001909578,0.00008287624,0.000008470229,0.0004133953,6.777243e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004222906,"about_ca_system_score_gemma":0.003233135,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00038064,"about_ca_topic_score_gemma":0.0002439179,"domain_scores_codex":[0.9971646,0.0002084823,0.001892184,0.0001851159,0.0003387604,0.0002108456],"domain_scores_gemma":[0.9961243,0.0008466337,0.002109214,0.0001592677,0.0005312697,0.0002293182],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9463388,0.01282364,0.02525796,0.00003585609,0.002170798,0.0001199153,0.0003956804,0.000147381,0.000008424442,0.000005169323,0.00008796329,0.01260836],"study_design_scores_gemma":[0.9316074,0.05310173,0.01059268,0.0002924645,0.003769055,0.000005701278,0.0000530584,0.00002760351,0.0001183547,0.000007579977,0.0003341824,0.00009020005],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9944122,0.0003296216,0.0001643846,0.001274907,0.0004033178,0.002057663,0.000005549364,0.000005462451,0.001346844],"genre_scores_gemma":[0.9959084,0.0007866677,0.002392752,0.0003744359,0.0002827246,0.00005651735,0.00001018772,0.00002323203,0.0001651274],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04027809,"threshold_uncertainty_score":0.5735443,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2373606074","doi":"10.1016/j.ejca.2016.03.081","title":"RECIST 1.1—Update and clarification: From the RECIST committee","year":2016,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1894,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Queen's University","funders":"Canadian Cancer Society Research Institute; National Cancer Institute; National Cancer Research Institute","keywords":"Response Evaluation Criteria in Solid Tumors; Medicine; Medical physics; Radiology; Disease; Progressive disease; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.02242408296974398,"gpt":0.3170312627307039,"spread":0.29460717976096,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002968982,0.00006933054,0.0001245368,0.00002138324,0.00008296892,0.00002657281,0.00009291719,0.00001070658,0.0003734255],"category_scores_gemma":[0.0000577356,0.00003043376,0.00004933706,0.00005344315,0.00008391327,0.00007962236,0.00001616593,0.0001087572,0.00003761339],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007267913,"about_ca_system_score_gemma":0.00008565142,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003778134,"about_ca_topic_score_gemma":0.00002080284,"domain_scores_codex":[0.9993033,0.0001283246,0.0002438411,0.00008520279,0.0001622052,0.00007712717],"domain_scores_gemma":[0.9992548,0.00009361139,0.0002049381,0.0001811945,0.000176863,0.00008861797],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002202504,0.00003892681,0.02291673,0.00000366385,0.0003603479,0.0001129253,0.0004494032,7.601432e-7,0.002245894,0.0003192328,0.08184233,0.8914895],"study_design_scores_gemma":[0.001785116,0.000102123,0.249012,0.0002207409,0.0002612474,0.00005147165,0.00006075106,6.067427e-7,0.0002797748,0.0001506128,0.7480345,0.00004103059],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.4696411,0.06545828,0.006790713,0.3917363,0.002328979,0.0004842983,0.0002492021,0.00004351158,0.06326764],"genre_scores_gemma":[0.9848295,0.005507943,0.001124479,0.002432642,0.001156635,0.000002280925,0.0000034021,0.00002285207,0.004920198],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8914485,"threshold_uncertainty_score":0.4088747,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1970476748","doi":"10.1056/nejmoa050736","title":"Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome","year":2005,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1854,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Queen's University; University of Ottawa; Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Erlotinib; Medicine; Lung cancer; Epidermal growth factor receptor; Oncology; Internal medicine; Clinical trial; Erlotinib Hydrochloride; Placebo; Cancer; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.02248944063098263,"gpt":0.4079720786852618,"spread":0.3854826380542792,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005360182,0.00009116565,0.00051013,0.0001593255,0.00001043777,0.000001848399,0.0000451064,0.00005227055,0.0001381634],"category_scores_gemma":[0.0002707614,0.00005503228,0.00006150176,0.0001138839,0.00008256218,0.00005531785,0.000009418583,0.0002394846,2.807961e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006855273,"about_ca_system_score_gemma":0.0002042566,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002344175,"about_ca_topic_score_gemma":0.0001583421,"domain_scores_codex":[0.9986653,0.00004595557,0.0008121125,0.00008952934,0.0002760074,0.000111086],"domain_scores_gemma":[0.9991391,0.0001351626,0.0002859536,0.00008859159,0.0001122988,0.0002389246],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0003215131,0.0001079643,0.924545,0.00004706744,0.0002712784,0.0001198349,0.0007952291,0.00005102861,0.0002669687,0.00004427222,0.001542303,0.07188755],"study_design_scores_gemma":[0.1045138,0.001996647,0.8653772,0.00112849,0.001691163,0.0004209162,0.0001682712,0.000197673,0.0002480769,0.00006085693,0.02411159,0.00008528016],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9754986,0.008429029,0.000151559,0.01451358,0.0004347043,0.0001616137,0.000002784804,0.000003909144,0.0008042461],"genre_scores_gemma":[0.9949937,0.001357363,0.000709283,0.0006073512,0.002003053,0.000001223134,0.000002137703,0.00001006295,0.0003157908],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1041923,"threshold_uncertainty_score":0.2244151,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2127342594","doi":"10.1056/nejmoa043623","title":"Vinorelbine plus Cisplatin vs. Observation in Resected Non–Small-Cell Lung Cancer","year":2005,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1832,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Cancer Institute","keywords":"Medicine; Vinorelbine; Internal medicine; Neutropenia; Lung cancer; Gastroenterology; Surgery; Hazard ratio; Chemotherapy; Regimen; Cisplatin; Confidence interval","retraction":null,"screen_n_in":null,"score":{"opus":0.02142726019502914,"gpt":0.3306539613456979,"spread":0.3092267011506687,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003812565,0.0001538222,0.000476379,0.000296889,0.00003872287,0.000007272498,0.00008377633,0.00007323376,0.0005064707],"category_scores_gemma":[0.0001533588,0.0001000935,0.0000543464,0.000359744,0.00003148737,0.0001248325,0.00001138048,0.0003639155,0.000003217096],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005057794,"about_ca_system_score_gemma":0.0007279635,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001268197,"about_ca_topic_score_gemma":0.00138933,"domain_scores_codex":[0.9985894,0.00004092195,0.0006304168,0.0001355778,0.000392329,0.0002113468],"domain_scores_gemma":[0.9988947,0.0001213259,0.0003148052,0.0001409029,0.0002673994,0.0002608763],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.005209085,0.0005504707,0.5744138,0.0003866159,0.0005657173,0.0009341816,0.01527722,0.00583939,0.02584737,0.00008277658,0.07931929,0.2915741],"study_design_scores_gemma":[0.2910544,0.003168545,0.5979757,0.003498012,0.001850196,0.000645488,0.0004524532,0.009289528,0.00296434,0.0000960818,0.08872175,0.0002834837],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9612037,0.00474124,0.0006139488,0.03032029,0.00045643,0.0003295017,0.000003183138,0.00001154255,0.002320177],"genre_scores_gemma":[0.9861509,0.001245642,0.002340944,0.00139052,0.004841879,0.000008192221,0.00002613112,0.00002222019,0.003973604],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2912906,"threshold_uncertainty_score":0.5545499,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2042386784","doi":"10.1016/j.cell.2012.08.029","title":"Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing","year":2012,"lang":"en","type":"article","venue":"Cell","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1826,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"National Cancer Institute; National Human Genome Research Institute; Canadian Institutes of Health Research; National Institute of General Medical Sciences; Broad Institute","keywords":"Biology; Adenocarcinoma; Exome sequencing; Genetics; Gene; Lung cancer; Mutation; Exome; Somatic cell; Context (archaeology); ARID1A; Germline mutation; Cancer research; Cancer; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.02714034130342818,"gpt":0.2718057737046342,"spread":0.244665432401206,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006122566,0.00007147285,0.0001141849,0.00003099743,0.00005818109,0.000004647017,0.00004075326,0.00002546023,0.00008653635],"category_scores_gemma":[0.000004871788,0.00003859123,0.000036023,0.00008854128,0.00004122287,0.00005596477,0.00001295624,0.00006904012,0.0000107512],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001042375,"about_ca_system_score_gemma":0.0001146069,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00009091513,"about_ca_topic_score_gemma":0.000003512465,"domain_scores_codex":[0.9995304,0.0000137624,0.0001019933,0.00007791001,0.000109535,0.0001664455],"domain_scores_gemma":[0.9996265,0.00003232661,0.00006759483,0.0001654682,0.0000424442,0.00006570837],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0001124307,0.0002197719,0.9599537,0.0004375699,0.0004257996,0.00004495554,0.02022694,0.0001095758,0.01226252,0.0005952835,0.004513989,0.001097443],"study_design_scores_gemma":[0.003309426,0.0002394236,0.9661696,0.0002924578,0.0007615807,0.000121562,0.007959596,0.0004537544,0.01295844,0.0000406351,0.00749565,0.0001978944],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9201739,0.00526796,0.001857304,0.0007893683,0.0001022512,0.0004460746,0.000004727779,0.00002368931,0.07133472],"genre_scores_gemma":[0.9945489,0.00002483143,0.002096904,0.0001935648,0.00009247556,0.00002408807,0.00001019119,0.00001181262,0.00299728],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07437494,"threshold_uncertainty_score":0.1573705,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3172081492","doi":"10.1056/nejmoa2103695","title":"Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation","year":2021,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1769,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute; Amgen","keywords":"KRAS; Medicine; Lung cancer; Mutation; Lung; Cancer research; Internal medicine; Oncology; Cancer; Biology; Genetics; Colorectal cancer; Gene","retraction":null,"screen_n_in":null,"score":{"opus":0.01351052059467178,"gpt":0.330700063136702,"spread":0.3171895425420302,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001908492,0.0001109942,0.0003544453,0.00008588367,0.00005501588,0.000008432898,0.00003550597,0.00003406966,0.0001707501],"category_scores_gemma":[0.0001682616,0.00006378548,0.0000607836,0.0001676342,0.00004230377,0.00008541009,0.00000358058,0.0001298663,5.802493e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002277058,"about_ca_system_score_gemma":0.001388087,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001140697,"about_ca_topic_score_gemma":0.000141605,"domain_scores_codex":[0.9991041,0.00002281241,0.0003031399,0.0001092385,0.000319733,0.0001409921],"domain_scores_gemma":[0.9987437,0.0001419407,0.0002156128,0.0001027663,0.0005532407,0.0002427354],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.009375643,0.0005025679,0.08799161,0.0009144127,0.00507677,0.006837981,0.01553321,0.002069941,0.01630168,0.00147455,0.2956988,0.5582228],"study_design_scores_gemma":[0.4241933,0.01287641,0.0214867,0.004045074,0.008745055,0.01848011,0.003966631,0.0006838965,0.01074925,0.001102244,0.4932739,0.0003974735],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.767608,0.02487331,0.08858533,0.1010214,0.003425677,0.001407483,0.00003675,0.00005657621,0.0129854],"genre_scores_gemma":[0.9819384,0.0004324677,0.007781825,0.001954836,0.00449578,0.00001048205,0.00006235056,0.00002628131,0.003297603],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5578253,"threshold_uncertainty_score":0.2601096,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3087210493","doi":"10.1056/nejmoa2027071","title":"Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer","year":2020,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1756,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Chugai Pharmaceutical; EMD Serono; Genentech; Ono Pharmaceutical; Shionogi; Loxo Oncology; Astellas Pharma; Mirati Therapeutics; Daiichi Sankyo Europe; Sanofi; Halozyme; F. Hoffmann-La Roche; Taiho Pharmaceutical; Regeneron Pharmaceuticals; Spectrum Pharmaceuticals; Amgen; Kyorin Pharmaceutical; Pfizer; Symphogen; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Osimertinib; Lung cancer; Medicine; Cancer research; Oncology; Internal medicine; Cancer; Epidermal growth factor receptor; Erlotinib","retraction":null,"screen_n_in":null,"score":{"opus":0.02115782651282301,"gpt":0.3285523371855753,"spread":0.3073945106727523,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002316386,0.0001627476,0.0005433959,0.0001719984,0.0000321662,0.00000678835,0.0001012528,0.00006186243,0.0005348768],"category_scores_gemma":[0.0002123346,0.0001038249,0.00006682524,0.0004911753,0.00004065764,0.00007047797,0.00001499311,0.0004384398,0.000004377656],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001460121,"about_ca_system_score_gemma":0.0006956827,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007926428,"about_ca_topic_score_gemma":0.0001283836,"domain_scores_codex":[0.9985901,0.00005463085,0.0006080365,0.0001580137,0.000362944,0.000226266],"domain_scores_gemma":[0.9987491,0.0001121343,0.0002772973,0.0001074689,0.0002263675,0.0005276645],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.008863322,0.0006726448,0.442763,0.0007954821,0.001451082,0.006415727,0.04081506,0.00136348,0.1571451,0.00002868516,0.2065099,0.1331765],"study_design_scores_gemma":[0.6366388,0.01103991,0.1559671,0.005800881,0.005756808,0.001327383,0.002571154,0.005066777,0.02186112,0.0001353729,0.1531862,0.0006484483],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9204416,0.007810311,0.0004856003,0.06614082,0.0005192994,0.0004013996,0.000005905919,0.00002068832,0.004174431],"genre_scores_gemma":[0.9901901,0.001023071,0.0004298344,0.004566629,0.003059323,0.000005506594,0.00001544143,0.00002615036,0.0006839475],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6277755,"threshold_uncertainty_score":0.5856526,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2132870547","doi":"10.1016/s1470-2045(14)71173-8","title":"Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1580,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University","funders":"Boehringer Ingelheim","keywords":"Medicine; Afatinib; Pemetrexed; Lung cancer; Internal medicine; Adenocarcinoma; Lung; Gemcitabine; Chemotherapy; Population; Gastroenterology; Oncology; Cisplatin; Surgery; Gefitinib; Epidermal growth factor receptor; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.1710050663165039,"gpt":0.4951860196022361,"spread":0.3241809532857323,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001940474,0.0002310315,0.001719452,0.0001567495,0.0001091328,0.00002635559,0.0002478204,0.0001143298,0.0001921946],"category_scores_gemma":[0.0009088597,0.0001580474,0.0002067423,0.0002964599,0.0001497884,0.0001038509,0.00004832793,0.0001361102,0.000001883236],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003370136,"about_ca_system_score_gemma":0.0006911011,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009631529,"about_ca_topic_score_gemma":0.0003780268,"domain_scores_codex":[0.997747,0.0005902059,0.0006582255,0.0004483922,0.0002613775,0.0002948028],"domain_scores_gemma":[0.9928087,0.005467508,0.0005859752,0.0007228797,0.0002635863,0.00015133],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6963817,0.002798289,0.1101823,0.0003810475,0.08172291,0.0002253592,0.01956422,0.005411376,0.00422535,0.002161017,0.04137653,0.03556987],"study_design_scores_gemma":[0.6607468,0.001862386,0.0232797,0.00007401693,0.03959235,0.000006313746,0.0008956725,0.269698,0.0009662139,0.0002645481,0.002319049,0.0002949757],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9628026,0.004286501,0.01524548,0.006349942,0.000820927,0.003638968,0.004468661,0.00005839936,0.002328557],"genre_scores_gemma":[0.9868315,0.000106595,0.004777963,0.0008298031,0.0008806532,0.0002107292,0.006212393,0.0000326443,0.0001177421],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2642866,"threshold_uncertainty_score":0.6444986,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3215921195","doi":"10.1016/j.jtho.2021.11.003","title":"The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015","year":2021,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1481,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"National Cancer Institute; BeiGene; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Grading (engineering); SMARCA4; Pathology; Immunohistochemistry; Lung; Adenoma; Internal medicine; Biology","retraction":null,"screen_n_in":null,"score":{"opus":0.04722255255441719,"gpt":0.5551534797927689,"spread":0.5079309272383516,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006505621,0.0002052654,0.002240338,0.0001947155,0.00005597908,0.00001051565,0.0002031278,0.0002014581,0.00008707104],"category_scores_gemma":[0.0003541228,0.0001053976,0.0009712265,0.0003731679,0.0001547257,0.0001115605,0.00003319611,0.0004364573,0.000002524531],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001079946,"about_ca_system_score_gemma":0.00599609,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001228831,"about_ca_topic_score_gemma":0.00000941654,"domain_scores_codex":[0.9976317,0.0003961294,0.001357257,0.0001434157,0.0003038589,0.0001676611],"domain_scores_gemma":[0.9945281,0.0006016486,0.00356413,0.0003192695,0.0008745484,0.0001123237],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001224042,0.0002704467,0.0001271839,0.003169578,0.001502612,0.0000952583,0.0001085038,0.000004301909,0.00001018396,0.00006990983,0.00396398,0.9905556],"study_design_scores_gemma":[0.0003062798,0.001487518,0.0006056532,0.0171862,0.006332136,0.001146178,0.0002247258,0.000008572837,0.000009682637,0.00003437225,0.9725764,0.00008227395],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001574823,0.996583,0.00007067555,0.0006273242,0.000520502,0.0003646765,0.00004361376,0.000001780565,0.001630919],"genre_scores_gemma":[0.0008023061,0.9972743,0.0006130818,0.000009247232,0.0004068365,0.00001467185,0.00003409848,0.00002140248,0.0008240627],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9904734,"threshold_uncertainty_score":0.999639,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1974903221","doi":"10.1056/nejmoa1311107","title":"Ceritinib in <i>ALK</i> -Rearranged Non–Small-Cell Lung Cancer","year":2014,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1475,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Ceritinib; Crizotinib; Anaplastic lymphoma kinase; Medicine; ALK inhibitor; Internal medicine; Lung cancer; Oncology; Gastroenterology","retraction":null,"screen_n_in":null,"score":{"opus":0.01245342306717361,"gpt":0.3153880680622122,"spread":0.3029346449950386,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004954408,0.0001409618,0.0004936549,0.000204101,0.00003336269,0.000006540367,0.00008136399,0.00005746971,0.0003548578],"category_scores_gemma":[0.0001253626,0.0000892185,0.00006564883,0.0001947027,0.00004136772,0.00005910752,0.000009226118,0.0003128897,0.000003217067],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001220163,"about_ca_system_score_gemma":0.0003430441,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008338426,"about_ca_topic_score_gemma":0.0003640348,"domain_scores_codex":[0.998837,0.00005451459,0.0004682445,0.0001226197,0.0003102586,0.0002073415],"domain_scores_gemma":[0.9990371,0.0001340368,0.0002210968,0.0001378384,0.0001559347,0.0003139557],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001702955,0.0005236045,0.4114434,0.000487247,0.0004892977,0.0008009748,0.01051734,0.0002536768,0.02310241,0.0001152399,0.07248624,0.4780776],"study_design_scores_gemma":[0.3373525,0.003963793,0.1294683,0.004574111,0.002522457,0.001260267,0.0008051234,0.0007501801,0.002374484,0.0003414989,0.5162488,0.0003385356],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9168141,0.007210538,0.001359348,0.02630239,0.001221105,0.0003758187,0.000004106535,0.00001545261,0.04669718],"genre_scores_gemma":[0.9898785,0.000950534,0.0007290269,0.001760121,0.004506444,0.000006249545,0.000007320189,0.00002168138,0.002140165],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4777391,"threshold_uncertainty_score":0.3885444,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1978236936","doi":"10.1097/jto.0b013e318290868f","title":"Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology","year":2013,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1284,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Queen's University","funders":"National Cancer Institute","keywords":"Medicine; Guideline; Lung cancer; Tyrosine kinase; Oncology; Internal medicine; Cancer; Selection (genetic algorithm); Pathology; Receptor","retraction":null,"screen_n_in":null,"score":{"opus":0.01468322786349575,"gpt":0.4181217731418935,"spread":0.4034385452783977,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001101557,0.0001335259,0.0005602887,0.0001043162,0.00010151,0.000008736016,0.00009426556,0.0001138566,0.000003672904],"category_scores_gemma":[0.002916398,0.00008752329,0.0001234659,0.0001633129,0.00005512157,0.00008579626,0.00003139375,0.0001029363,8.633668e-9],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008748955,"about_ca_system_score_gemma":0.0003508107,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009421066,"about_ca_topic_score_gemma":0.0002941427,"domain_scores_codex":[0.9981847,0.0001169564,0.001105348,0.0001775159,0.000246091,0.0001693838],"domain_scores_gemma":[0.9908876,0.001609382,0.0030493,0.00008657191,0.004324454,0.00004263028],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.003296339,0.002190355,0.7534816,0.0003121476,0.004239749,0.000003853183,0.001946174,0.001967333,0.07527795,0.00006530039,0.03613245,0.1210868],"study_design_scores_gemma":[0.06831558,0.05139733,0.5245193,0.001355036,0.03779818,0.00006388778,0.01072967,0.2072919,0.06583489,0.002415873,0.02938524,0.000893111],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.972452,0.001614657,0.01154049,0.008826332,0.0005759196,0.003644345,0.001332821,0.000004647952,0.000008775725],"genre_scores_gemma":[0.9779192,0.0001576825,0.02019308,0.0004450917,0.0003316619,0.0007891649,0.00009508368,0.00002306485,0.00004599239],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2289623,"threshold_uncertainty_score":0.3569096,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2122553809","doi":"10.1016/s0140-6736(08)61758-4","title":"Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial","year":2008,"lang":"en","type":"article","venue":"The Lancet","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1243,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; McGill University Health Centre","funders":"AstraZeneca","keywords":"Gefitinib; Docetaxel; Medicine; Lung cancer; Internal medicine; Regimen; Hazard ratio; Population; Oncology; Chemotherapy; Performance status; Cancer; Epidermal growth factor receptor; Confidence interval","retraction":null,"screen_n_in":null,"score":{"opus":0.06467038308692118,"gpt":0.372727022308989,"spread":0.3080566392220678,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001647679,0.0001886662,0.0006496646,0.0000636446,0.0001131731,0.00001601145,0.0001499723,0.00006312109,0.000291964],"category_scores_gemma":[0.00004287633,0.000115551,0.000134579,0.0002061107,0.00006444277,0.00004827473,0.00002259441,0.0001989592,0.00002086532],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000202714,"about_ca_system_score_gemma":0.0002846683,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001160546,"about_ca_topic_score_gemma":0.000486877,"domain_scores_codex":[0.9988611,0.00006963344,0.0003206289,0.0002438875,0.0001360053,0.0003687957],"domain_scores_gemma":[0.999163,0.0001553315,0.0001189886,0.0004154182,0.00004862803,0.00009861447],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9415668,0.00175049,0.005048682,0.0001625316,0.0009113163,0.0004614597,0.007478592,0.00005993482,0.001457818,0.00003441894,0.03755748,0.003510497],"study_design_scores_gemma":[0.9908744,0.0007734036,0.001321931,0.0001832833,0.0008298834,0.00001979858,0.00009998307,0.0005732393,0.001359536,0.000006228552,0.003811683,0.0001466404],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9813842,0.001642845,0.00002094315,0.001535263,0.0003803073,0.003014932,0.00004888175,0.00006507992,0.01190754],"genre_scores_gemma":[0.9922267,0.001261035,0.000088339,0.000454466,0.001041949,0.0008977948,0.00007321842,0.00002690569,0.003929591],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0493076,"threshold_uncertainty_score":0.4712034,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2132165198","doi":"10.1038/nm.1790","title":"Gene expression–based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study","year":2008,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1243,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; Queen's University; University Health Network","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute; U.S. Public Health Service","keywords":"Lung cancer; Adenocarcinoma; Oncology; Stage (stratigraphy); Internal medicine; Covariate; Microarray analysis techniques; Survival analysis; Microarray; Medicine; Cancer; Bioinformatics; Gene expression; Gene; Biology; Computer science; Machine learning; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.036264107200383,"gpt":0.3620844392133409,"spread":0.325820332012958,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002954101,0.000233749,0.0004378493,0.0004360405,0.0001483918,0.000005059271,0.00007812752,0.0002650568,0.0002099568],"category_scores_gemma":[0.000267012,0.0001659282,0.00005771855,0.0006531604,0.00007467265,0.0001111098,0.00002091861,0.0006338199,0.00001199341],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003193161,"about_ca_system_score_gemma":0.0002325816,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002087205,"about_ca_topic_score_gemma":0.00008173749,"domain_scores_codex":[0.9980437,0.0001156733,0.0004259813,0.0004628134,0.000700179,0.0002516463],"domain_scores_gemma":[0.9989926,0.00009914668,0.0001186956,0.0004002299,0.0002173232,0.0001720522],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0004079058,0.001549152,0.9821187,0.0000539239,0.00008962901,0.0004824211,0.002977915,0.00008018252,0.009920326,0.000003577243,0.002067086,0.0002491456],"study_design_scores_gemma":[0.02579014,0.0008275188,0.962884,0.0002358122,0.00041216,0.00006172496,0.0005833433,0.001408604,0.007440229,0.000004032267,0.0002245541,0.0001278553],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9919159,0.002387187,0.000996537,0.001288483,0.0008249139,0.001725334,0.00002701176,0.0001276106,0.000707051],"genre_scores_gemma":[0.9958125,0.00003025893,0.001489861,0.00039102,0.0005611708,0.0001556112,0.0005282003,0.00003334914,0.0009980623],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02538224,"threshold_uncertainty_score":0.6766355,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2339311613","doi":"10.1016/s1470-2045(16)30033-x","title":"Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1175,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency; Ottawa Hospital; McGill University","funders":"European Society for Medical Oncology; Boehringer Ingelheim","keywords":"Afatinib; Gefitinib; Medicine; Internal medicine; Lung cancer; Oncology; Population; Clinical endpoint; Randomized controlled trial; Epidermal growth factor receptor; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.04042620639566981,"gpt":0.4065506950648967,"spread":0.3661244886692269,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002352811,0.0003075065,0.00142477,0.00007388002,0.0001933913,0.00002012219,0.0002023628,0.0001179528,0.000493466],"category_scores_gemma":[0.0001226553,0.0001415464,0.0001159827,0.0001615019,0.0001584755,0.00008705397,0.0000411895,0.00008712494,0.00001582127],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009452555,"about_ca_system_score_gemma":0.001120376,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000580292,"about_ca_topic_score_gemma":0.0004465189,"domain_scores_codex":[0.9982007,0.0002314077,0.0005529703,0.0003777637,0.000232213,0.0004049102],"domain_scores_gemma":[0.9968024,0.001705522,0.0005971078,0.000405926,0.0003468392,0.0001421456],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9712113,0.007917766,0.001283275,0.00004638662,0.003003733,0.00007304434,0.002394652,0.00002792342,0.0002379191,0.0001118487,0.0008476084,0.01284453],"study_design_scores_gemma":[0.9616703,0.02868703,0.0007298147,0.0001602804,0.004510461,0.000004461681,0.000117229,0.0002494579,0.001016346,0.00001948099,0.002663488,0.0001716445],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9650932,0.0005435644,0.0002460594,0.00524533,0.0006972963,0.01468585,0.0004183065,0.00003504416,0.01303537],"genre_scores_gemma":[0.9889732,0.0005944843,0.0005554717,0.0004622824,0.0006250659,0.006309278,0.0002389847,0.00004320517,0.002198035],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02388001,"threshold_uncertainty_score":0.5772094,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3101089668","doi":"10.1056/nejmoa2027187","title":"First-Line Lorlatinib or Crizotinib in Advanced <i>ALK</i> -Positive Lung Cancer","year":2020,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1064,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"Cancer Research UK; Pfizer","keywords":"Crizotinib; Anaplastic lymphoma kinase; ALK inhibitor; Lung cancer; Cancer research; Medicine; Internal medicine; Oncology","retraction":null,"screen_n_in":null,"score":{"opus":0.02574200789427179,"gpt":0.3619308581690756,"spread":0.3361888502748038,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001881834,0.0001799682,0.0006228249,0.0001320421,0.00004347543,0.00000621325,0.00008661972,0.00005254117,0.0008370893],"category_scores_gemma":[0.0004679251,0.0001037938,0.00007031879,0.0003837851,0.00005256844,0.0001302139,0.00001534994,0.0003726282,0.000002965439],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000156517,"about_ca_system_score_gemma":0.0005429093,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002374205,"about_ca_topic_score_gemma":0.0003568133,"domain_scores_codex":[0.9985543,0.00003981164,0.000625823,0.0001705753,0.0003949944,0.0002145004],"domain_scores_gemma":[0.9986582,0.0002383409,0.0003026045,0.00009892556,0.0002197005,0.0004822059],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.02891268,0.0006824973,0.1819829,0.0007792889,0.001710264,0.007249681,0.04372637,0.006589578,0.004853966,0.0002338339,0.06568062,0.6575984],"study_design_scores_gemma":[0.5287751,0.01937861,0.08511787,0.009748519,0.003743489,0.002028319,0.002029042,0.003361043,0.002099274,0.0003154026,0.3428237,0.0005797039],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.606714,0.01757117,0.003784623,0.3609765,0.001702707,0.001137021,0.00004599905,0.000049659,0.008018327],"genre_scores_gemma":[0.9842443,0.002351634,0.001295176,0.006467469,0.004708517,0.000008022499,0.00001630565,0.00002808876,0.0008804889],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6570187,"threshold_uncertainty_score":0.9165541,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2154969724","doi":"10.1146/annurev-pathol-011110-130206","title":"EGFR Mutations and Lung Cancer","year":2011,"lang":"en","type":"review","venue":"Annual Review of Pathology Mechanisms of Disease","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":970,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Epidermal growth factor receptor; Tyrosine kinase; Protein kinase domain; Cancer research; Lung cancer; Mutation; Medicine; Receptor tyrosine kinase; Kinase; Targeted therapy; Mutant; EGFR inhibitors; Cancer; Biology; Oncology; Internal medicine; Gene; Receptor; Cell biology; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.02528738243119175,"gpt":0.4057506192605896,"spread":0.3804632368293979,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001836772,0.0003265764,0.002077632,0.0001671746,0.00004026933,0.000001757091,0.000117948,0.0001421225,0.0003655489],"category_scores_gemma":[0.0001884492,0.0002104322,0.0005321194,0.0002101217,0.0001491518,0.00006378238,0.00007071844,0.0001477306,0.000008035006],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005913049,"about_ca_system_score_gemma":0.001025894,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002261937,"about_ca_topic_score_gemma":0.000002020729,"domain_scores_codex":[0.9983466,0.0001482696,0.0007803118,0.0003784348,0.0001556786,0.0001906728],"domain_scores_gemma":[0.9982228,0.00007498695,0.0006748079,0.000445388,0.0003059049,0.0002761152],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00001442808,0.0002356025,0.000009521675,0.3854398,0.0006169801,0.0001469437,0.0001141839,1.672249e-8,8.217445e-7,0.007850523,0.0006641869,0.604907],"study_design_scores_gemma":[0.0008129266,0.0004725799,0.00009876613,0.4036945,0.07349412,0.0001540806,0.00006728699,8.260395e-7,0.000006740062,0.001660093,0.5191399,0.0003982487],"study_design_candidate":"systematic_review","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.000003236068,0.9944314,0.0002295093,0.000156329,0.0001654233,0.001908429,0.002682738,0.00001847188,0.0004044096],"genre_scores_gemma":[0.00002694489,0.996815,0.001030357,0.0003805415,0.00003717385,0.0006865296,0.0005440799,0.00004325642,0.0004361361],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.6045088,"threshold_uncertainty_score":0.8581178,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2152905269","doi":"10.1016/s1470-2045(12)70087-6","title":"Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial","year":2012,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":953,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Afatinib; Medicine; Erlotinib; Gefitinib; Internal medicine; Clinical endpoint; Hazard ratio; Placebo; Lung cancer; Oncology; Performance status; Chemotherapy; Adenocarcinoma; Randomized controlled trial; Surgery; Cancer; Epidermal growth factor receptor; Confidence interval; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.03765453655497886,"gpt":0.403575366148624,"spread":0.3659208295936452,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003379942,0.0002391219,0.001087578,0.00006591623,0.00006344567,0.000006362424,0.00009950212,0.0000724796,0.0002678263],"category_scores_gemma":[0.0001129962,0.0001242375,0.00009426897,0.0001504936,0.0001549481,0.00009107152,0.00002267321,0.0001230417,5.733701e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001139655,"about_ca_system_score_gemma":0.000561789,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005119908,"about_ca_topic_score_gemma":0.0002688627,"domain_scores_codex":[0.9986141,0.0001105615,0.0004716511,0.0002292963,0.0001736069,0.0004007506],"domain_scores_gemma":[0.9977745,0.001144522,0.0004864449,0.0002830955,0.0001958086,0.0001155962],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.975596,0.002711663,0.004561319,0.0007667326,0.001480576,0.000004393827,0.004030999,0.00001836582,0.0006087182,0.00002093107,0.0006881423,0.009512194],"study_design_scores_gemma":[0.9785327,0.00999559,0.00135243,0.0002539148,0.003679655,0.000005219171,0.0005117324,0.0002212097,0.001839414,0.000008430234,0.003420289,0.0001793807],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9895627,0.0009952454,0.0004913916,0.0009808997,0.000369853,0.006951853,0.0003394553,0.00002048766,0.0002880761],"genre_scores_gemma":[0.9720966,0.0004026507,0.02235164,0.0004536573,0.0006859982,0.003341239,0.00008571102,0.0000552057,0.0005272701],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02186025,"threshold_uncertainty_score":0.506626,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2125665528","doi":"10.1200/jco.2015.62.1342","title":"Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":851,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Hamilton Health Sciences","funders":"","keywords":"Medicine; Pemetrexed; Oncology; Gefitinib; Erlotinib; Internal medicine; Crizotinib; Docetaxel; Lung cancer; Carboplatin; Afatinib; Chemotherapy; Bevacizumab; Cancer; Epidermal growth factor receptor; Malignant pleural effusion; Cisplatin","retraction":null,"screen_n_in":null,"score":{"opus":0.197713970446764,"gpt":0.6016853804165807,"spread":0.4039714099698167,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.02242482,0.0003216325,0.00475002,0.00008456826,0.00007204941,0.00001343995,0.0004190161,0.0009345522,0.00007649123],"category_scores_gemma":[0.009520001,0.000219829,0.002280897,0.0002797329,0.0007520261,0.0002129917,0.0001019041,0.001866761,0.00001157162],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006707331,"about_ca_system_score_gemma":0.02385866,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003609189,"about_ca_topic_score_gemma":0.00008066391,"domain_scores_codex":[0.9857649,0.001726413,0.01086314,0.0005397198,0.000619793,0.0004860496],"domain_scores_gemma":[0.9696227,0.01120643,0.01275986,0.0005171089,0.004650167,0.001243687],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.02370962,0.01099924,0.1616081,0.0001492852,0.005429714,0.0002817456,0.0004654544,0.0001855371,0.00005584982,0.00006066464,0.3294579,0.4675969],"study_design_scores_gemma":[0.04931903,0.04594608,0.01439176,0.0001514182,0.003924577,0.0002277811,0.002395834,0.002435231,0.00002214343,0.00004171534,0.8809467,0.0001977548],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8612616,0.008705594,0.01579753,0.09367865,0.01101939,0.002836435,0.0001559484,0.00004611282,0.006498754],"genre_scores_gemma":[0.4978086,0.0678947,0.3476489,0.06964326,0.01405097,0.0001420964,0.00006962448,0.0001400555,0.002601716],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5514888,"threshold_uncertainty_score":0.9988232,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2154662831","doi":"10.1200/jco.2011.36.8456","title":"First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":735,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"CAE (Canada)","funders":"","keywords":"Medicine; Gemcitabine; Oncology; Cisplatin; Internal medicine; Adenocarcinoma; Lung cancer; Chemotherapy; Lung; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.131847856307436,"gpt":0.4544081414491074,"spread":0.3225602851416715,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001132495,0.0001242383,0.000868991,0.0000857998,0.00004878544,0.000004700831,0.00009673184,0.0002047449,0.00008877162],"category_scores_gemma":[0.00101509,0.00006643039,0.0002092914,0.0001646055,0.0002140116,0.0001534202,0.00004498988,0.0005127918,0.000001102197],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000259805,"about_ca_system_score_gemma":0.0006019919,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00006605978,"about_ca_topic_score_gemma":0.0002121316,"domain_scores_codex":[0.9978109,0.0001881185,0.001355249,0.0001209165,0.0003067394,0.0002180574],"domain_scores_gemma":[0.9963461,0.001955316,0.001127626,0.0001588354,0.0001659442,0.0002461687],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1444475,0.004127061,0.8319159,0.00008146858,0.001001504,0.0001585905,0.0008542404,0.0002328038,0.00001470958,0.0001257488,0.002564531,0.01447601],"study_design_scores_gemma":[0.177702,0.02201027,0.7803341,0.0002598517,0.001713976,0.0001409761,0.000241478,0.0001727528,0.00003624574,0.00003417115,0.01726624,0.0000879452],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9860841,0.002260067,0.00006485897,0.008937546,0.001282863,0.0004528147,0.000003664948,0.000003383202,0.0009107091],"genre_scores_gemma":[0.9973752,0.0002309676,0.0009193295,0.0004303172,0.0008709772,0.000007946593,0.000001621541,0.00001387952,0.0001497538],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05158179,"threshold_uncertainty_score":0.2708953,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2139939379","doi":"10.1634/theoncologist.2008-0232","title":"The Differential Efficacy of Pemetrexed According to NSCLC Histology: A Review of Two Phase III Studies","year":2009,"lang":"en","type":"review","venue":"The Oncologist","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":692,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Eli Lilly (Canada)","funders":"Eli Lilly and Company","keywords":"Pemetrexed; Medicine; Docetaxel; Gemcitabine; Oncology; Internal medicine; Histology; Hazard ratio; Lung cancer; Proportional hazards model; Chemotherapy; Cisplatin; Confidence interval","retraction":null,"screen_n_in":null,"score":{"opus":0.1300508911499699,"gpt":0.5312090846097777,"spread":0.4011581934598078,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004384688,0.000319641,0.002834746,0.00009321517,0.0001969784,0.000006276103,0.0003723884,0.0000825932,0.00004308552],"category_scores_gemma":[0.0009386429,0.0001327197,0.0006444834,0.0004353654,0.0003995465,0.00001387896,0.0001270985,0.0002515511,0.000008685005],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005451803,"about_ca_system_score_gemma":0.0006003399,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007285988,"about_ca_topic_score_gemma":0.00003363924,"domain_scores_codex":[0.9979765,0.0002938058,0.0009788941,0.0002683737,0.0002426732,0.0002397723],"domain_scores_gemma":[0.9967241,0.001360483,0.0009245576,0.0007104091,0.0002133877,0.00006701805],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001169376,0.000451582,0.000001191399,0.01496809,0.001451907,0.00001630974,0.0001336686,1.002546e-7,0.000001852276,0.0003201208,0.00931328,0.9732249],"study_design_scores_gemma":[0.00338651,0.00115491,0.000008244431,0.06865012,0.01647945,0.00005038065,0.0001401824,3.299835e-7,0.000002323922,0.00002637835,0.9099799,0.0001212836],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00004824423,0.9918813,0.00002882233,0.002314094,0.0004243297,0.003050809,0.00003989056,0.00002452061,0.002187969],"genre_scores_gemma":[0.0005840316,0.9972361,0.0001053195,0.0003225997,0.0001993053,0.0003014162,0.00006199741,0.00002186735,0.001167357],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9731037,"threshold_uncertainty_score":0.5412151,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2105026490","doi":"10.1200/jco.2007.14.8924","title":"Role of <i>KRAS</i> and <i>EGFR</i> As Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":665,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"Princess Margaret Cancer Centre; Queen's University; University Health Network; University of Toronto; Ontario Institute for Cancer Research","funders":"National Cancer Institute","keywords":"Erlotinib; KRAS; Medicine; Epidermal growth factor receptor; Hazard ratio; Fluorescence in situ hybridization; EGFR inhibitors; Internal medicine; Oncology; Erlotinib Hydrochloride; Cancer research; Cancer; Biology; Gene; Colorectal cancer; Genetics; Confidence interval","retraction":null,"screen_n_in":null,"score":{"opus":0.1692448192514435,"gpt":0.5560504929225468,"spread":0.3868056736711033,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.01226896,0.0001211286,0.002259805,0.0002082199,0.00002877827,0.000001469214,0.0001257618,0.0001934005,0.00005428785],"category_scores_gemma":[0.01918736,0.0000869868,0.000296888,0.0002891482,0.0003134618,0.00008328952,0.00004473938,0.0003668423,4.01375e-7],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002974233,"about_ca_system_score_gemma":0.0167258,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.03538412,"about_ca_topic_score_gemma":0.09725235,"domain_scores_codex":[0.9923346,0.001571964,0.005094852,0.000198457,0.0006419923,0.0001581274],"domain_scores_gemma":[0.9893016,0.006695404,0.002712283,0.0001378758,0.0008031431,0.0003496826],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.06258963,0.006076464,0.8902227,0.00003827105,0.002367932,0.0003429398,0.0008674911,0.00008974974,0.002401716,0.00006733015,0.009072067,0.02586373],"study_design_scores_gemma":[0.02368397,0.016457,0.9189883,0.0001676571,0.0006069365,0.00009771717,0.0007349998,0.000009943181,0.0001998259,0.0000938048,0.03888576,0.0000741145],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9919086,0.000641709,0.000005597446,0.004614903,0.001031743,0.0006178043,0.00005343138,0.00000164819,0.001124564],"genre_scores_gemma":[0.9965467,0.0005884502,0.001072104,0.001316783,0.000301235,0.00001296301,0.000002297962,0.000009676074,0.000149788],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06186823,"threshold_uncertainty_score":0.9890745,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4242460399","doi":"10.1200/jco.2017.74.6065","title":"Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":650,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"Association for Molecular Pathology; American Society of Clinical Oncology; American Association for Cancer Research","keywords":"Medicine; Atezolizumab; Nivolumab; Pembrolizumab; Oncology; Internal medicine; Lung cancer; Guideline; Docetaxel; Pemetrexed; Chemotherapy; Clinical trial; Cancer; Intensive care medicine; Immunotherapy; Pathology; Cisplatin","retraction":null,"screen_n_in":null,"score":{"opus":0.1717391177742632,"gpt":0.6087778275094344,"spread":0.4370387097351712,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0183093,0.0003246709,0.004850917,0.00006719801,0.0002403596,0.00003019542,0.0006985956,0.0009576943,0.0001152921],"category_scores_gemma":[0.0112593,0.0002228826,0.002728456,0.0001097408,0.001160702,0.0002873887,0.0001502291,0.001951039,0.00000936966],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004431918,"about_ca_system_score_gemma":0.01504408,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004892409,"about_ca_topic_score_gemma":0.0001279159,"domain_scores_codex":[0.9870637,0.001194286,0.01016255,0.0005719644,0.0005153668,0.0004921332],"domain_scores_gemma":[0.9640853,0.01052566,0.02039605,0.0008910674,0.003268436,0.0008334182],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.01632763,0.008300833,0.2458611,0.0001727013,0.005490426,0.0002810082,0.000215581,0.00004878906,0.00009396282,0.00006430926,0.1402985,0.5828452],"study_design_scores_gemma":[0.04253079,0.03173495,0.08790016,0.0002171951,0.004237401,0.0001679212,0.0009185782,0.001800206,0.00003164012,0.00003544058,0.8302231,0.0002026381],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8572881,0.004488583,0.008674434,0.109483,0.01023564,0.002482694,0.0001638903,0.00003064304,0.007153092],"genre_scores_gemma":[0.6560702,0.09026978,0.2009502,0.0385616,0.01144553,0.0001066895,0.00003498455,0.0001046807,0.00245637],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6899245,"threshold_uncertainty_score":0.9970693,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2115330744","doi":"10.1093/annonc/mdq020","title":"Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)","year":2010,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":644,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Bevacizumab; Medicine; Gemcitabine; Hazard ratio; Clinical endpoint; Internal medicine; Placebo; Lung cancer; Oncology; Cisplatin; Progression-free survival; Chemotherapy; Confidence interval; Surgery; Urology; Gastroenterology; Clinical trial; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.0480325960961244,"gpt":0.4125897085681237,"spread":0.3645571124719993,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003924069,0.0002756609,0.0009516519,0.0001050865,0.0001407789,0.00001647467,0.0001027271,0.0002283768,0.0002703296],"category_scores_gemma":[0.0002245995,0.0001802393,0.0001374173,0.0001089403,0.0001336072,0.00007596688,0.00002434716,0.0002206683,0.000002052645],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005091915,"about_ca_system_score_gemma":0.001267885,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002762407,"about_ca_topic_score_gemma":0.004626695,"domain_scores_codex":[0.9983355,0.00005714193,0.0006184321,0.0004583981,0.0001852674,0.000345286],"domain_scores_gemma":[0.9971866,0.001455798,0.0004418093,0.0003345599,0.0003619861,0.0002192204],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.95913,0.002417821,0.0001705119,0.00006263411,0.0009744425,0.00007885626,0.002021065,0.00002208375,0.003748786,0.00002711362,0.003690789,0.02765583],"study_design_scores_gemma":[0.9376195,0.02738834,0.0003035609,0.00007558196,0.0008278352,0.00001952854,0.0001149942,0.00090202,0.005866012,0.00007637573,0.02659218,0.0002140559],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9837746,0.0005276717,0.0002621557,0.005897157,0.0005610621,0.005474567,0.0008119228,0.00003131544,0.002659566],"genre_scores_gemma":[0.9903521,0.001792139,0.002188531,0.0008966856,0.0006873684,0.001110469,0.0004785166,0.00004761791,0.00244657],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02744178,"threshold_uncertainty_score":0.7349944,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2536396512","doi":"10.1016/s1470-2045(16)30508-3","title":"Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":643,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta; Princess Margaret Cancer Centre; University of Ottawa; Ottawa Hospital","funders":"National Cancer Institute; AstraZeneca","keywords":"Osimertinib; Lung cancer; Medicine; Open label; Cancer; Oncology; Internal medicine; Adenocarcinoma; Clinical trial","retraction":null,"screen_n_in":null,"score":{"opus":0.06472232217388303,"gpt":0.4461270129553907,"spread":0.3814046907815077,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002899945,0.0003004284,0.0008288603,0.00006545162,0.0002620687,0.00003291011,0.000380403,0.0001131544,0.0002209092],"category_scores_gemma":[0.000104655,0.0001590921,0.00006806381,0.000223886,0.0001140625,0.0001492713,0.0001416532,0.0001517541,0.00002681182],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009073223,"about_ca_system_score_gemma":0.0005248894,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003757329,"about_ca_topic_score_gemma":0.0004342368,"domain_scores_codex":[0.9981059,0.0001871259,0.0003962126,0.0005374667,0.0001495447,0.0006236819],"domain_scores_gemma":[0.9979934,0.0006895262,0.0002975699,0.0005575694,0.0002992473,0.0001626951],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.04916632,0.08704337,0.05548121,0.0004343129,0.007315743,0.0004341015,0.02535572,0.0000543868,0.1803924,0.0003490316,0.0249066,0.5690668],"study_design_scores_gemma":[0.7143987,0.06837609,0.01912476,0.001299872,0.01326909,0.00007615656,0.005322096,0.00233491,0.06395339,0.0002106853,0.1103705,0.001263748],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9651523,0.001376153,0.001128864,0.00899554,0.0006565645,0.01068486,0.0004654779,0.0001141647,0.01142614],"genre_scores_gemma":[0.9860511,0.0002440882,0.002633173,0.002522177,0.0004469859,0.003326079,0.000063111,0.0000646687,0.004648625],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6652324,"threshold_uncertainty_score":0.6487586,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2784623697","doi":"10.1016/j.jtho.2017.12.001","title":"Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors","year":2018,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":633,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Guideline; Medicine; KRAS; ROS1; Lung cancer; Context (archaeology); Targeted therapy; Companion diagnostic; Pathology; Oncology; Internal medicine; Medical physics; Adenocarcinoma; Cancer; Family medicine; Intensive care medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.01968033351421288,"gpt":0.4325975365504492,"spread":0.4129172030362364,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001873788,0.0001117959,0.0003264164,0.0001019586,0.0001108627,0.000005605483,0.00004421736,0.00006190335,0.00002495795],"category_scores_gemma":[0.0001268274,0.00005857726,0.00009450291,0.0002236621,0.00006279778,0.00005386417,0.000006563862,0.00004775223,1.721223e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006472847,"about_ca_system_score_gemma":0.0007642954,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000951473,"about_ca_topic_score_gemma":0.00007106923,"domain_scores_codex":[0.9990926,0.00003115724,0.0004885342,0.0001059487,0.000128496,0.0001532221],"domain_scores_gemma":[0.9968703,0.0001347073,0.0006693891,0.00007745054,0.00218122,0.0000669185],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.02311816,0.004399671,0.1003319,0.0002917147,0.006001273,0.00003391282,0.001557405,0.001579183,0.1088872,0.00003495806,0.05008541,0.7036792],"study_design_scores_gemma":[0.03075139,0.1412712,0.01988017,0.0008877107,0.02174987,0.0003049715,0.0005625074,0.02696247,0.5148374,0.0001281039,0.2422535,0.0004107355],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9775223,0.001134889,0.01473983,0.003942586,0.0006854003,0.001728113,0.00008019186,0.00001295345,0.0001537424],"genre_scores_gemma":[0.9600015,0.00002485233,0.03878789,0.0003336147,0.0005338405,0.000107999,0.00004371796,0.00002287714,0.000143712],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7032685,"threshold_uncertainty_score":0.2388711,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3191219220","doi":"10.1200/jco.21.00662","title":"Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":632,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Institute for Health and Care Research; Manchester Biomedical Research Centre; Cedars-Sinai Medical Center","keywords":"Medicine; Rash; Lung cancer; Internal medicine; Population; Adverse effect; Epidermal growth factor receptor; Erlotinib; Oncology; Gastroenterology; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.1015364525497676,"gpt":0.5266134971143889,"spread":0.4250770445646213,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001183252,0.0001740695,0.0009824904,0.00007997068,0.00008477805,0.00003065366,0.0001345367,0.000227686,0.0001378892],"category_scores_gemma":[0.001034276,0.000105942,0.0002358768,0.0002794336,0.0000903725,0.00009561219,0.00003472001,0.0009960374,0.000003962022],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004483917,"about_ca_system_score_gemma":0.003564687,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004444147,"about_ca_topic_score_gemma":0.00121618,"domain_scores_codex":[0.996493,0.0005593845,0.002070295,0.0002962473,0.000352025,0.0002289987],"domain_scores_gemma":[0.9958752,0.001982724,0.001293323,0.0002498797,0.000408921,0.0001899471],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.05543217,0.05502504,0.3633374,0.00004865158,0.003382659,0.01287372,0.01552988,0.0004617559,0.002838843,0.000004613083,0.01154782,0.4795175],"study_design_scores_gemma":[0.2408612,0.02464205,0.7027282,0.001186406,0.002773611,0.0001395304,0.005461652,0.001827846,0.003108516,0.0000767053,0.016903,0.0002913299],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9757372,0.0006486306,0.00003112613,0.02009044,0.001153671,0.0006341472,0.00005683922,0.00001151669,0.001636389],"genre_scores_gemma":[0.9924316,0.0003721838,0.0007263827,0.004565611,0.001541631,0.00002792431,0.00005241988,0.00002731685,0.0002549387],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4792261,"threshold_uncertainty_score":0.6323602,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4379280261","doi":"10.1056/nejmoa2304594","title":"Overall Survival with Osimertinib in Resected <i>EGFR</i> -Mutated NSCLC","year":2023,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":612,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"AstraZeneca","keywords":"Medicine; Osimertinib; Internal medicine; Hazard ratio; Placebo; Clinical endpoint; Lung cancer; Regimen; Population; Oncology; Surgery; Confidence interval; Cancer; Clinical trial; Epidermal growth factor receptor; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.02339926590478572,"gpt":0.3316075296963627,"spread":0.308208263791577,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005088511,0.0001396326,0.0004730496,0.0003899748,0.00003367982,0.000006767368,0.00007211368,0.00004717168,0.0001972333],"category_scores_gemma":[0.0002541283,0.00007780948,0.00004290621,0.0007093137,0.00005984757,0.00008397349,0.00001049143,0.0003157839,0.00001191708],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001071179,"about_ca_system_score_gemma":0.0004363706,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004735355,"about_ca_topic_score_gemma":0.0002409722,"domain_scores_codex":[0.9985622,0.00007046477,0.0004609493,0.000128743,0.0005377331,0.0002399009],"domain_scores_gemma":[0.9989545,0.0002175673,0.0001931843,0.0001376224,0.0002120326,0.0002850438],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.02698984,0.0008614506,0.5117085,0.0002832494,0.002613948,0.02310222,0.01967359,0.001464169,0.0380911,0.0005331751,0.150032,0.2246468],"study_design_scores_gemma":[0.3535835,0.009009226,0.5580348,0.003032559,0.001074505,0.002362594,0.001247202,0.0002490365,0.0008428463,0.0007058778,0.06959198,0.0002659465],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9707304,0.0006294597,0.0001073345,0.02176456,0.000511476,0.0002229703,0.000003353847,0.000040742,0.005989746],"genre_scores_gemma":[0.9952894,0.0003334073,0.0001952199,0.0005604554,0.001459588,0.000002675306,0.00004014317,0.00002455078,0.002094583],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3265936,"threshold_uncertainty_score":0.3172978,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3013446577","doi":"10.1016/s0140-6736(20)30164-1","title":"Small molecules, big impact: 20 years of targeted therapy in oncology","year":2020,"lang":"en","type":"review","venue":"The Lancet","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":602,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Clinical trial; Drug development; Drug; Precision medicine; Targeted therapy; Oncology; Bioinformatics; Cancer; Pharmacology; Internal medicine; Pathology; Biology","retraction":null,"screen_n_in":null,"score":{"opus":0.1072282215240836,"gpt":0.4180433705636626,"spread":0.310815149039579,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001002051,0.000157451,0.001591173,0.00006848076,0.00001058253,0.000004498781,0.0001736441,0.0001203353,0.00006800454],"category_scores_gemma":[0.00003351865,0.00008607719,0.0002275241,0.0002896828,0.0000426565,0.000006112421,0.00002516812,0.0002707825,0.00002993892],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000218764,"about_ca_system_score_gemma":0.0008471593,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002228093,"about_ca_topic_score_gemma":0.00006204906,"domain_scores_codex":[0.9992082,0.0001106331,0.000268792,0.000154774,0.00008478922,0.0001728775],"domain_scores_gemma":[0.9993056,0.0001050228,0.0001695798,0.000346188,0.00002225154,0.00005134897],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00006047404,0.00007556736,0.00004778937,0.0007057287,0.0005738928,0.00009006889,0.000347736,0.000001105629,0.000003762548,0.00004016116,0.003301089,0.9947526],"study_design_scores_gemma":[0.001506259,0.0004054155,0.000647836,0.001230213,0.0005225079,0.00002684789,0.0000131997,0.000002461431,0.000001818472,0.00004002136,0.9955317,0.00007170928],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001452292,0.9949996,0.000004562043,0.0009755275,0.0001088699,0.0007915614,0.0001999294,0.0000194192,0.002755252],"genre_scores_gemma":[0.0001405644,0.9982083,0.0002241093,0.000392166,0.0004693636,0.0000884577,0.0002698611,0.00002970063,0.000177476],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9946809,"threshold_uncertainty_score":0.3510126,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2168841302","doi":"10.1158/1078-0432.ccr-06-0462","title":"Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib","year":2006,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":584,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute","keywords":"Gefitinib; Erlotinib; Epidermal growth factor receptor; Lung cancer; Medicine; Exon; Erlotinib Hydrochloride; Internal medicine; Oncology; Mutation; Point mutation; Cancer research; Cancer; Biology; Genetics; Gene","retraction":null,"screen_n_in":null,"score":{"opus":0.09555870628366898,"gpt":0.4421776627540716,"spread":0.3466189564704026,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007054659,0.0002700491,0.000741532,0.0002944828,0.0001768658,0.00003073741,0.0001506397,0.0002393796,0.0004187336],"category_scores_gemma":[0.0006262294,0.0001755263,0.0001060549,0.001259884,0.0003548791,0.0001274714,0.00004137557,0.0007322975,0.000006178212],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009557963,"about_ca_system_score_gemma":0.001744686,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.01536161,"about_ca_topic_score_gemma":0.03673966,"domain_scores_codex":[0.9963158,0.0005585487,0.0008835108,0.0006603707,0.0009032055,0.0006785153],"domain_scores_gemma":[0.995999,0.001190272,0.0004280214,0.0002751647,0.001825065,0.000282432],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.004338038,0.002557354,0.9901222,0.0002573708,0.0002617722,0.00005466775,0.0003205388,0.00007979645,0.00011422,0.000007793925,0.0009974502,0.0008888219],"study_design_scores_gemma":[0.0153547,0.002440531,0.9791524,0.0009285022,0.0002869193,8.026468e-7,0.0002195647,0.0001865279,0.0010789,0.000007956555,0.0001314965,0.0002117197],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9942827,0.0002213896,0.00001920961,0.0009471248,0.0001068707,0.002921811,0.0007402553,0.00004927252,0.000711414],"genre_scores_gemma":[0.9948967,0.0001918302,0.000197938,0.000079234,0.0001903405,0.001401071,0.0007243604,0.00007051534,0.002248019],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02137805,"threshold_uncertainty_score":0.9911952,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2623725180","doi":"10.1016/s1470-2045(17)30339-x","title":"Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":580,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"Ignyta; Shionogi; AstraZeneca; Associazione Italiana per la Ricerca sul Cancro; Astellas Pharma; Eli Lilly and Company","keywords":"Ceritinib; Crizotinib; Medicine; Anaplastic lymphoma kinase; Lung cancer; ALK inhibitor; Internal medicine; Chemotherapy; Oncology; Docetaxel; Pemetrexed; Gastroenterology; Cisplatin","retraction":null,"screen_n_in":null,"score":{"opus":0.04534884463340635,"gpt":0.4133336191056075,"spread":0.3679847744722012,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005353074,0.000284415,0.001357203,0.00005401842,0.0003321462,0.0001076257,0.0004219557,0.000139019,0.0001817426],"category_scores_gemma":[0.00007924026,0.0001696143,0.00006359263,0.00006837053,0.0002177148,0.0001329887,0.00006758898,0.0002747787,0.000003323039],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002794537,"about_ca_system_score_gemma":0.0005413057,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008576998,"about_ca_topic_score_gemma":0.001133105,"domain_scores_codex":[0.9983894,0.0001773786,0.0003723526,0.0004106437,0.0001751844,0.0004750034],"domain_scores_gemma":[0.998349,0.0002817703,0.0004563984,0.0006519094,0.0001256746,0.0001352317],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9393207,0.003042432,0.02021008,0.00007383629,0.0009590885,0.00003108732,0.002250622,0.000001448145,0.0001488185,0.00001233337,0.004122496,0.02982705],"study_design_scores_gemma":[0.9631067,0.006986218,0.01318767,0.0001386486,0.0006674747,0.000002782725,0.0001026312,0.0000950685,0.00009492955,0.00001090322,0.01541561,0.0001914008],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9619135,0.0006901593,0.00001527056,0.008796905,0.0005643225,0.01096955,0.00006133995,0.00002805908,0.01696088],"genre_scores_gemma":[0.9910239,0.001594936,0.0006561208,0.002203633,0.0007178829,0.002614627,0.00004700763,0.00006047343,0.001081427],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02963565,"threshold_uncertainty_score":0.6916672,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2153865661","doi":"10.1200/jco.2007.14.4824","title":"Phase III Trial of Maintenance Gefitinib or Placebo After Concurrent Chemoradiotherapy and Docetaxel Consolidation in Inoperable Stage III Non–Small-Cell Lung Cancer: SWOG S0023","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":573,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Sunnybrook Health Science Centre","funders":"National Cancer Institute; Sanofi; AstraZeneca","keywords":"Medicine; Gefitinib; Docetaxel; Internal medicine; Performance status; Lung cancer; Interim analysis; Placebo; Chemoradiotherapy; Surgery; Oncology; Chemotherapy; Cancer; Clinical trial; Epidermal growth factor receptor; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.08398044194763006,"gpt":0.4845825549230046,"spread":0.4006021129753746,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001003203,0.000156193,0.001540953,0.000125947,0.00003957357,0.000006352112,0.00008021138,0.0002209595,0.000408609],"category_scores_gemma":[0.0003349259,0.000102589,0.0001934163,0.0001374767,0.0002454322,0.0001209852,0.00001990745,0.0005165501,0.000001103295],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002852862,"about_ca_system_score_gemma":0.003239344,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001740722,"about_ca_topic_score_gemma":0.0001551703,"domain_scores_codex":[0.9971541,0.0001677479,0.002037222,0.0002057027,0.0002071593,0.0002280776],"domain_scores_gemma":[0.9971268,0.0007732587,0.001399535,0.0001313107,0.0003219937,0.0002470879],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7778994,0.02129056,0.06148108,0.0003956021,0.001508622,0.003328592,0.004371811,0.0001088427,0.001508533,0.00006294561,0.008458226,0.1195857],"study_design_scores_gemma":[0.9239024,0.02480921,0.01020983,0.0004375014,0.0008062646,0.0002965793,0.0003865482,0.0009541483,0.0009024261,0.000009952805,0.03709943,0.0001856991],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9932073,0.001622103,0.0003108735,0.001767671,0.0009521753,0.0009519549,0.00003024589,0.00000462287,0.001153091],"genre_scores_gemma":[0.9819543,0.01262007,0.001009932,0.001091025,0.0006117297,0.00006880928,0.000006004421,0.00001624895,0.002621886],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1460029,"threshold_uncertainty_score":0.5746458,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4319337483","doi":"10.1016/s0140-6736(23)00221-0","title":"Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial","year":2023,"lang":"en","type":"article","venue":"The Lancet","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":566,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Five Prime Therapeutics; AstraZeneca; Amgen","keywords":"Docetaxel; Medicine; Internal medicine; Oncology; Lung cancer; Cancer; Taxane; Progressive disease; Chemotherapy; Breast cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.0813253911151174,"gpt":0.4193913372672951,"spread":0.3380659461521777,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000291601,0.0002086425,0.0006059607,0.00005818728,0.0002486086,0.0001026551,0.0002527655,0.00005587701,0.0001125494],"category_scores_gemma":[0.00005460923,0.0001189048,0.00006705392,0.0004053674,0.00005144598,0.000100412,0.00003750882,0.0001100338,0.00002940698],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001653179,"about_ca_system_score_gemma":0.0004876779,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000355505,"about_ca_topic_score_gemma":0.0002058275,"domain_scores_codex":[0.9988057,0.0000497362,0.0002496376,0.0003140544,0.0001829793,0.0003978838],"domain_scores_gemma":[0.9988394,0.0002992636,0.000154555,0.0004542076,0.0001414139,0.0001111194],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9052442,0.001166154,0.0006401457,0.000409785,0.002031175,0.0001222616,0.002911488,0.0001419344,0.0008323744,0.00009636719,0.08123653,0.005167601],"study_design_scores_gemma":[0.9788359,0.002962296,0.0001629636,0.0001852579,0.002798522,0.000007764187,0.0002183942,0.00240595,0.0009226967,0.00002571323,0.01129465,0.0001799025],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9715325,0.0009001064,0.0004759634,0.005691376,0.0006416482,0.01385814,0.0003289006,0.0002056053,0.006365745],"genre_scores_gemma":[0.9509923,0.0008340577,0.001790185,0.00118227,0.003206102,0.01805398,0.001558257,0.0001338581,0.02224902],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0735917,"threshold_uncertainty_score":0.4848796,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2587420003","doi":"10.1093/annonc/mdw611","title":"Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":522,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency; Ottawa Hospital; McGill University","funders":"Chugai Pharmaceutical; Genentech; Ono Pharmaceutical; Astellas Pharma; Chinese University of Hong Kong; GlaxoSmithKline; AstraZeneca Korea; Clovis Oncology; Vertex Pharmaceuticals; International Association for the Study of Lung Cancer; Amgen; ACEA Biosciences; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company","keywords":"Gefitinib; Afatinib; Medicine; Internal medicine; Lung cancer; Hazard ratio; Oncology; Epidermal growth factor receptor; T790M; Proportional hazards model; Gastroenterology; Confidence interval; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.08223081129384406,"gpt":0.4570319687057121,"spread":0.374801157411868,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002110978,0.0001980079,0.0005134832,0.00005275829,0.0002184923,0.00002845619,0.0004100123,0.0001094776,0.0001310517],"category_scores_gemma":[0.0002139502,0.0001374086,0.0000628543,0.00006975306,0.00014539,0.0002841666,0.0001367249,0.0001991474,0.000004529621],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001519508,"about_ca_system_score_gemma":0.0009045755,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004860412,"about_ca_topic_score_gemma":0.00325611,"domain_scores_codex":[0.9985179,0.0001036527,0.0003949507,0.000425882,0.0002565163,0.0003011113],"domain_scores_gemma":[0.99751,0.0005897768,0.000584762,0.0008863868,0.0003264374,0.0001026627],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4374608,0.01234429,0.3731115,0.0001566773,0.004163429,0.0003828336,0.009790896,0.0003911106,0.0002532324,0.0002016497,0.0150372,0.1467064],"study_design_scores_gemma":[0.5263442,0.01104405,0.4545453,0.000318082,0.001319141,9.300358e-7,0.0006896824,0.0009254987,0.0006052862,0.00003582943,0.003885781,0.0002862249],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9853675,0.0003797855,0.00004137723,0.003095615,0.0009961897,0.001850919,0.001815455,0.00001193774,0.006441195],"genre_scores_gemma":[0.9958762,0.0002306448,0.0004865179,0.0005101748,0.0003018615,0.000166329,0.002230125,0.00002617568,0.0001719901],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1464202,"threshold_uncertainty_score":0.7347522,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1979840121","doi":"10.1002/ijc.27339","title":"Cigarette smoking and lung cancer—relative risk estimates for the major histological types from a pooled analysis of case–control studies","year":2011,"lang":"en","type":"article","venue":"International Journal of Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":503,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true},"ca_institutions":"Institut National de la Recherche Scientifique; Université de Montréal","funders":"National Cancer Institute; Canadian Institutes of Health Research; National Institutes of Health","keywords":"Lung cancer; Medicine; Cancer; Relative risk; Lung; Case-control study; Cigarette smoking; Environmental health; Oncology; Internal medicine; Pathology; Confidence interval","retraction":null,"screen_n_in":null,"score":{"opus":0.03076127353565602,"gpt":0.3906267141087815,"spread":0.3598654405731255,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001297419,0.00008615231,0.000342667,0.0001429473,0.00006228522,0.000009098566,0.00007665122,0.00003304686,0.0002241373],"category_scores_gemma":[0.0001948327,0.0000475418,0.0001767443,0.00008916774,0.0000940705,0.00008599061,0.00001509711,0.0001028959,4.898338e-8],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002502163,"about_ca_system_score_gemma":0.0001127046,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001895223,"about_ca_topic_score_gemma":0.0009121629,"domain_scores_codex":[0.9992884,0.00002197784,0.0003109068,0.00009601226,0.00020929,0.00007338954],"domain_scores_gemma":[0.9979751,0.000623369,0.0005233372,0.00005522506,0.0007844776,0.00003853367],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"meta_analysis","study_design_gemma":"observational","study_design_scores_codex":[0.001291895,0.00008395179,0.445612,0.00001416499,0.5252672,0.0002530334,0.005588705,0.0008084588,0.0001131202,0.000418142,0.0003775158,0.02017172],"study_design_scores_gemma":[0.005625811,0.0002594255,0.5444964,0.0003354521,0.4331858,0.0001197523,0.001037875,0.01191969,0.0006833876,0.00196736,0.0002562203,0.0001127739],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.6169333,0.3690124,0.009295183,0.002719674,0.0008112779,0.0002782473,0.0008480035,0.000006206558,0.00009572392],"genre_scores_gemma":[0.9968842,0.001688122,0.0009001346,0.0002402546,0.000183293,0.0000507719,0.000003562024,0.000006424212,0.00004321029],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3799509,"threshold_uncertainty_score":0.2865022,"prediction_status":"machine_predicted_unvalidated"},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"meta_analysis","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"meta_analysis","genre":"review","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W2104748005","doi":"10.1200/jco.2009.24.3030","title":"Molecular Predictors of Outcome With Gefitinib and Docetaxel in Previously Treated Non–Small-Cell Lung Cancer: Data From the Randomized Phase III INTEREST Trial","year":2009,"lang":"en","type":"letter","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":492,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Gefitinib; Docetaxel; Medicine; Lung cancer; Oncology; Internal medicine; Biomarker; Hazard ratio; Epidermal growth factor receptor; KRAS; Cancer; Confidence interval; Biology; Colorectal cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.1212243943653459,"gpt":0.490069456183446,"spread":0.3688450618181001,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.002496931,0.000352216,0.004883724,0.0001613636,0.00002962682,0.00002010165,0.0005057906,0.0008673124,0.00008355481],"category_scores_gemma":[0.001545905,0.0001725228,0.0005412506,0.0001402265,0.0004005752,0.0000910666,0.00009693721,0.002737694,6.251437e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002005285,"about_ca_system_score_gemma":0.002525939,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001042989,"about_ca_topic_score_gemma":0.0005115237,"domain_scores_codex":[0.9936299,0.001090453,0.004178382,0.0004306356,0.0003852832,0.0002852864],"domain_scores_gemma":[0.9891506,0.005244972,0.00447746,0.0006299021,0.0002997381,0.0001973491],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8106689,0.003145466,0.01950856,0.0001520699,0.007168279,0.005506893,0.0003856138,0.00001201393,0.00001181739,0.000001423305,0.1440438,0.009395188],"study_design_scores_gemma":[0.9193437,0.01050053,0.001722064,0.001002279,0.02014992,0.00008685639,0.00004527777,0.0001960388,0.00001008002,0.00001925697,0.0467663,0.0001577679],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8127968,0.005029476,0.0001105621,0.17714,0.001008063,0.003065058,0.000292911,0.000007282604,0.0005498023],"genre_scores_gemma":[0.6755992,0.01404104,0.002142958,0.2910148,0.0141834,0.0002129334,0.001562406,0.0001464513,0.001096768],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1371976,"threshold_uncertainty_score":0.999563,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2925139051","doi":"10.1016/j.jtho.2019.03.007","title":"Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":491,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"Merck Sharp and Dohme; Genentech; F. Hoffmann-La Roche; Amgen; Ariad Pharmaceuticals; Roche; Novartis; Celgene; Bristol-Myers Squibb; AstraZeneca; Pfizer; AbbVie; Merck","keywords":"Alectinib; Medicine; Lung cancer; Crizotinib; Oncology; Internal medicine; Cancer research","retraction":null,"screen_n_in":null,"score":{"opus":0.01789835229157475,"gpt":0.4489390676521736,"spread":0.4310407153605988,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008501753,0.0001674589,0.0005798031,0.0001010224,0.00006758477,0.000009902717,0.0002821469,0.00008271818,0.00005833247],"category_scores_gemma":[0.0001118061,0.00007306245,0.00006835082,0.0004748235,0.00008926426,0.00008248332,0.0001201639,0.0003598084,3.340352e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004670945,"about_ca_system_score_gemma":0.0007290599,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008148259,"about_ca_topic_score_gemma":0.0006822101,"domain_scores_codex":[0.9982459,0.0005353066,0.0005995787,0.0002154903,0.0002191368,0.0001845783],"domain_scores_gemma":[0.9980102,0.0006791332,0.0006800909,0.0004216589,0.0001466893,0.00006224732],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.07940067,0.02353687,0.6442787,0.0001632163,0.003032545,0.0007233075,0.03783946,0.004763978,0.01454678,0.00003804474,0.00069111,0.1909853],"study_design_scores_gemma":[0.0302048,0.007596022,0.9545509,0.0004934862,0.001373475,0.0002166999,0.003645932,0.001317605,0.0003526843,0.00001054452,0.0001515456,0.00008626714],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9941905,0.000612337,0.00001043805,0.001867264,0.0001519361,0.00198448,0.0001646415,0.000002114677,0.001016304],"genre_scores_gemma":[0.9994185,0.0002570551,0.00006387488,0.000143572,0.00003987213,0.000007212532,0.00001840373,0.000009440504,0.00004208929],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3102722,"threshold_uncertainty_score":0.29794,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2295354328","doi":"10.1016/s1470-2045(15)00614-2","title":"Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":470,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Ignyta; National Institutes of Health; University of Washington; Astex Pharmaceuticals; Eli Lilly and Company; Novartis Institutes for BioMedical Research; Ariad Pharmaceuticals; Genentech; Pfizer; Novartis Pharmaceuticals Corporation; Chugai Pharmaceutical; Servier; Universität Heidelberg","keywords":"Ceritinib; Crizotinib; Medicine; ALK inhibitor; Internal medicine; Anaplastic lymphoma kinase; Lung cancer; Oncology; Tyrosine-kinase inhibitor; Clinical trial; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.04046967010096525,"gpt":0.3862219429664884,"spread":0.3457522728655231,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003047984,0.0001382181,0.0005039352,0.00002311775,0.00008770997,0.00001042963,0.0001949395,0.00008004157,0.00008471293],"category_scores_gemma":[0.00006688003,0.0000582566,0.00001787895,0.0001232845,0.0001451938,0.00007634992,0.00008798479,0.0001502305,0.000002405981],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002259929,"about_ca_system_score_gemma":0.0003442295,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004069437,"about_ca_topic_score_gemma":0.003748997,"domain_scores_codex":[0.9988525,0.0002391814,0.0002672332,0.0002678013,0.0001235645,0.0002497243],"domain_scores_gemma":[0.9986581,0.0005590025,0.0002458317,0.0003847432,0.00009096927,0.00006132015],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7888225,0.006001228,0.09214197,0.00003862979,0.0008099222,0.00002769007,0.004775498,0.000003923829,0.005153148,0.00002364089,0.006076131,0.09612568],"study_design_scores_gemma":[0.7484642,0.002224434,0.2360903,0.0002249483,0.0005978648,9.232241e-7,0.0001359563,0.00007396033,0.001007501,0.000008897867,0.01105976,0.0001113241],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9830551,0.0001323248,0.00002001965,0.009349887,0.0001864919,0.002628687,0.00122665,0.00001243212,0.003388473],"genre_scores_gemma":[0.9980693,0.0003371984,0.00028475,0.0005450668,0.0002039483,0.0001543595,0.0001212141,0.00001593756,0.0002681925],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1439483,"threshold_uncertainty_score":0.6151798,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2138200001","doi":"10.1016/j.jmoldx.2013.03.001","title":"Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors","year":2013,"lang":"en","type":"article","venue":"Journal of Molecular Diagnostics","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":461,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Kingston General Hospital; Queen's University","funders":"","keywords":"Guideline; Anaplastic lymphoma kinase; Medicine; Lung cancer; Family medicine; Oncology; Internal medicine; Epidermal growth factor receptor; Cancer; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.009204737053342864,"gpt":0.3159489873506346,"spread":0.3067442502972917,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001073892,0.000122297,0.000270797,0.0001186522,0.00004894075,0.00001719002,0.00003685988,0.00006043332,0.000007289178],"category_scores_gemma":[0.001811452,0.0001000997,0.0001090463,0.000138186,0.0000266724,0.00007912699,0.00001364451,0.0000737606,1.392162e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001260502,"about_ca_system_score_gemma":0.0001926417,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007514211,"about_ca_topic_score_gemma":0.00000328389,"domain_scores_codex":[0.9989568,0.00001398886,0.0005584607,0.0001118487,0.0002035815,0.0001553062],"domain_scores_gemma":[0.9970258,0.0002346701,0.0004436417,0.00006905691,0.002101043,0.0001257472],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0004175264,0.002227357,0.4058188,0.001520204,0.002088072,0.00005753263,0.0004192014,0.004994815,0.4088742,0.0003586584,0.08853325,0.08469041],"study_design_scores_gemma":[0.02909761,0.009824278,0.05430645,0.003236767,0.009125453,0.0001217027,0.000150006,0.02475515,0.8551894,0.001466452,0.0120794,0.0006473116],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9552337,0.004197354,0.03773127,0.001131109,0.0002719052,0.001321508,0.00005906075,0.000007338757,0.00004678645],"genre_scores_gemma":[0.9507393,0.0002147487,0.04814791,0.0005504326,0.0001635969,0.0001016318,0.00003437019,0.00003445302,0.00001357523],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4463153,"threshold_uncertainty_score":0.4081946,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2137043950","doi":"10.1016/s1470-2045(15)00006-6","title":"Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":434,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Ottawa","funders":"AstraZeneca; Eli Lilly and Company","keywords":"Afatinib; Erlotinib; Medicine; Clinical endpoint; Internal medicine; Lung cancer; Erlotinib Hydrochloride; Oncology; Population; Randomized controlled trial; Surgery; Cancer; Epidermal growth factor receptor","retraction":null,"screen_n_in":null,"score":{"opus":0.06509205628352367,"gpt":0.4127227631918144,"spread":0.3476307069082907,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003492747,0.0002335339,0.001350148,0.00004453721,0.00009729912,0.00001038063,0.0003046327,0.0000904564,0.0001334277],"category_scores_gemma":[0.0001741514,0.0001075242,0.00009228451,0.0001591239,0.0001726234,0.00008804508,0.00005223423,0.0001090367,0.000002892664],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004205942,"about_ca_system_score_gemma":0.001189816,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001877679,"about_ca_topic_score_gemma":0.0001685925,"domain_scores_codex":[0.9982089,0.0004341275,0.0005355892,0.0002670282,0.0002638419,0.0002905076],"domain_scores_gemma":[0.9976114,0.0005994525,0.0006505811,0.0006642896,0.0003278182,0.0001464419],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9791286,0.01068667,0.002162092,0.00003937075,0.0005056114,0.00001486743,0.003292011,0.00007134538,0.0003634615,0.00009852868,0.0006981763,0.002939288],"study_design_scores_gemma":[0.9307817,0.06107069,0.001151708,0.00001570981,0.002065402,0.000003483395,0.0005008799,0.0003674442,0.00176022,0.00002114295,0.002158171,0.0001034996],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9760129,0.0005500681,0.000009805794,0.0006435172,0.000720855,0.009161214,0.0001753493,0.00001866931,0.01270762],"genre_scores_gemma":[0.9970236,0.0000153502,0.0004210868,0.0002180873,0.0002644222,0.0008515902,0.0001679471,0.00002942902,0.001008429],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05038402,"threshold_uncertainty_score":0.438471,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2514360855","doi":"10.5858/arpa.2012-0720-oa","title":"Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology","year":2013,"lang":"en","type":"article","venue":"Archives of Pathology & Laboratory Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":428,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Queen's University","funders":"National Cancer Institute","keywords":"Guideline; Medicine; Anaplastic lymphoma kinase; Lung cancer; Family medicine; Oncology; Internal medicine; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.009531255861994709,"gpt":0.3332404848885003,"spread":0.3237092290265056,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007197483,0.0001871852,0.000634271,0.0001279015,0.0001087022,0.000002898968,0.000110531,0.00008846525,0.000003597686],"category_scores_gemma":[0.003853431,0.0001247443,0.00007469,0.0002139779,0.0002991642,0.00005633414,0.00004412659,0.00008956058,8.728303e-9],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001636178,"about_ca_system_score_gemma":0.0002251016,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00105727,"about_ca_topic_score_gemma":0.0002618843,"domain_scores_codex":[0.9980889,0.0001409227,0.0009967413,0.0003281437,0.0002356912,0.0002096068],"domain_scores_gemma":[0.9932964,0.002480478,0.001669437,0.000175346,0.002330913,0.00004737751],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0006885352,0.0006553223,0.7176976,0.0002726065,0.001304259,0.000002283688,0.00356822,0.0002247261,0.2600905,0.0002279169,0.006589467,0.008678587],"study_design_scores_gemma":[0.05475611,0.01635418,0.7937823,0.00111811,0.01249956,0.000006626931,0.00804056,0.04971661,0.0577994,0.001862633,0.003524263,0.0005396687],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9733121,0.003058807,0.008236839,0.005181707,0.000331226,0.004923491,0.004933245,0.00001161633,0.00001099912],"genre_scores_gemma":[0.9855698,0.0002357925,0.01080032,0.0006097005,0.000216923,0.002022235,0.0004880826,0.00003152059,0.00002561068],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2022911,"threshold_uncertainty_score":0.5086925,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1814699096","doi":"10.1016/j.ctrv.2004.08.002","title":"Gefitinib does not improve survival when combined with paclitaxel and carboplatin chemotherapy in people with advanced non-small-cell lung cancer☆☆☆☆Abstracted from: Herbst RS, Giaccone G, Schiller JH et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial – INTACT 2. J Clin Oncol 2004;22:785–94.","year":2004,"lang":"en","type":"letter","venue":"Cancer Treatment Reviews","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":406,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Cancer Care Ontario","funders":"","keywords":"Gefitinib; Medicine; Carboplatin; Paclitaxel; Lung cancer; Chemotherapy; Oncology; Internal medicine; Tyrosine-kinase inhibitor; Epidermal growth factor receptor; Cancer; Cisplatin","retraction":null,"screen_n_in":null,"score":{"opus":0.01463295194877606,"gpt":0.3232133757697233,"spread":0.3085804238209472,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0005482406,0.002399033,0.005096148,0.0007073262,0.0002161865,0.0002321655,0.0003141035,0.0008183024,0.0002068429],"category_scores_gemma":[0.00003022522,0.00159857,0.0003004381,0.0009604993,0.0002409414,0.0006861713,0.00007457774,0.00211704,0.000001978097],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.006388156,"about_ca_system_score_gemma":0.004141427,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.08312356,"about_ca_topic_score_gemma":0.1598435,"domain_scores_codex":[0.9920209,0.0004654111,0.002375298,0.002831019,0.000821693,0.001485663],"domain_scores_gemma":[0.9950166,0.0005798415,0.002388271,0.001196044,0.0003452953,0.0004738976],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.2660007,0.02234966,0.4287684,0.01669342,0.008818368,0.004553122,0.04191408,0.002387171,0.0076031,0.00001550605,0.01103746,0.189859],"study_design_scores_gemma":[0.8783428,0.01689292,0.02626301,0.02598039,0.005993706,0.00002574494,0.001369648,0.0009150907,0.00266406,0.00001785244,0.03764297,0.003891816],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8928692,0.04255258,0.00006519874,0.03167735,0.0007036021,0.02897067,0.002573028,0.0001004572,0.000487968],"genre_scores_gemma":[0.5401073,0.2716936,0.009373163,0.06727476,0.001954939,0.08897269,0.01299256,0.001474981,0.006156041],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6123421,"threshold_uncertainty_score":0.9988747,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4387882142","doi":"10.1016/j.annonc.2023.10.117","title":"Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":396,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University Health Centre; BC Cancer Agency","funders":"Daiichi Sankyo Europe; Gilead Sciences; National Cancer Institute; American College of Radiology Imaging Network; Society for Immunotherapy of Cancer; Pfizer Japan; Genentech; Mirati Therapeutics; Jounce Therapeutics; Chugai Pharmaceutical; MSD K.K.; Jazz Pharmaceuticals; Eli Lilly Japan; ECOG-ACRIN Cancer Research Group; Janssen Biotech; Helsinn; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; American Society of Clinical Oncology; Janssen Research and Development; EMD Serono; International Association for the Study of Lung Cancer; Sanofi; Amgen; Pfizer","keywords":"Medicine; Carboplatin; Chemotherapy; Internal medicine; Pemetrexed; Oncology; Chemotherapy regimen; Lung cancer; Hazard ratio; Osimertinib; Regimen; Progression-free survival; Phases of clinical research; Cancer; Cisplatin; Erlotinib; Epidermal growth factor receptor; Confidence interval","retraction":null,"screen_n_in":null,"score":{"opus":0.03675421611862686,"gpt":0.4300967680827514,"spread":0.3933425519641245,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002308398,0.0001782993,0.0004392857,0.00009283267,0.00006173489,0.000008793139,0.00007516012,0.00005776498,0.00002090695],"category_scores_gemma":[0.00008521603,0.00009916975,0.00004145613,0.0002576453,0.0001152579,0.00006507428,0.00004142772,0.000148165,0.000005389209],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007736996,"about_ca_system_score_gemma":0.0004544403,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001479182,"about_ca_topic_score_gemma":0.0001470017,"domain_scores_codex":[0.9986279,0.0001099515,0.0003811656,0.000388091,0.0002423886,0.0002504883],"domain_scores_gemma":[0.9989946,0.000223355,0.0001924933,0.0003501443,0.00008245584,0.0001568946],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.2744207,0.007906552,0.1477709,0.00005332194,0.0007548148,0.001069532,0.01530106,0.000046078,0.001708406,0.00001220515,0.001474682,0.5494817],"study_design_scores_gemma":[0.09542955,0.01480629,0.8767246,0.0005896676,0.0003265742,0.000006446307,0.001660765,0.0001631833,0.0009234059,0.00007549482,0.009115864,0.0001781437],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9813094,0.0004689016,0.000002736387,0.01516981,0.00006185504,0.001854055,0.000140164,0.00004815807,0.0009449866],"genre_scores_gemma":[0.99537,0.0003857031,0.0001225526,0.0032899,0.00005954666,0.000351941,0.0001730418,0.00002744081,0.0002199178],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7289537,"threshold_uncertainty_score":0.4044025,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1837617056","doi":"","title":"Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update.","year":2010,"lang":"en","type":"article","venue":"PubMed","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":389,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Epidermal growth factor receptor; Cancer research; Autophosphorylation; Receptor tyrosine kinase; Tyrosine kinase; Epidermal growth factor; GRB2; Tropomyosin receptor kinase C; Growth factor receptor; Platelet-derived growth factor receptor; Gefitinib; ROR1; Biology; Signal transduction; Growth factor receptor inhibitor; Medicine; Cell biology; Internal medicine; Cancer; Receptor; Growth factor; Kinase; Protein kinase A","retraction":null,"screen_n_in":null,"score":{"opus":0.02782150552786074,"gpt":0.3281403449556285,"spread":0.3003188394277678,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008054153,0.0001038026,0.0001843703,0.00007084217,0.00004040166,0.00002133683,0.00004244858,0.00006159746,0.0002893806],"category_scores_gemma":[0.00004482663,0.00008204578,0.00002648147,0.0001149247,0.00003454481,0.0001827129,0.00001805087,0.0001534398,0.000004336648],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00010066,"about_ca_system_score_gemma":0.00007151801,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009345674,"about_ca_topic_score_gemma":0.001041724,"domain_scores_codex":[0.9992601,0.00001987957,0.0001459808,0.0002137006,0.0001021737,0.0002581962],"domain_scores_gemma":[0.9995264,0.00002185704,0.00003936206,0.0001491726,0.0000391744,0.0002239657],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00005661835,0.0001817771,0.7608877,0.0001576752,0.0001034067,0.00001788219,0.0004539384,3.110569e-7,0.0003390052,0.001061518,0.002172431,0.2345677],"study_design_scores_gemma":[0.001465057,0.0000169885,0.9806696,0.00001901114,0.00008826517,0.000008731438,0.00002192269,0.00002829151,0.0005689087,0.00006429199,0.0169551,0.00009389169],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9896182,0.003481464,0.000002637676,0.004570784,0.0004322174,0.0008577617,0.00007131463,0.00004238,0.0009231869],"genre_scores_gemma":[0.9951027,0.001706646,0.0002305416,0.0008889209,0.0002023488,0.001325417,0.00005407299,0.00001791124,0.00047144],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2344738,"threshold_uncertainty_score":0.334573,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4318693852","doi":"10.1200/jco.22.02186","title":"Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":389,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"AstraZeneca (Canada); Princess Margaret Cancer Centre; University Health Network","funders":"National Center for Advancing Translational Sciences; AstraZeneca","keywords":"Medicine; Afatinib; Clinical endpoint; Internal medicine; Oncology; Osimertinib; Lung cancer; Hazard ratio; Cancer; Clinical trial; Stage (stratigraphy); Adenocarcinoma; Confidence interval; Erlotinib; Epidermal growth factor receptor","retraction":null,"screen_n_in":null,"score":{"opus":0.1084029731460099,"gpt":0.5189698770640995,"spread":0.4105669039180896,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.006126831,0.0002625988,0.002944269,0.0001600858,0.0001926824,0.00003010446,0.0003083349,0.0004215178,0.0002928297],"category_scores_gemma":[0.008428186,0.0001429454,0.001101028,0.0004956573,0.0002628464,0.00009924053,0.00006753308,0.0009711326,0.00001635065],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003024891,"about_ca_system_score_gemma":0.004966045,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008957332,"about_ca_topic_score_gemma":0.0002996278,"domain_scores_codex":[0.9930717,0.001055976,0.00457662,0.0003915923,0.0004511279,0.0004529793],"domain_scores_gemma":[0.9798626,0.01492204,0.003408493,0.0003795526,0.0009883463,0.0004390093],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8970804,0.001801553,0.0001590921,0.00001797819,0.003186971,0.0004542609,0.0009144054,0.0001281759,0.0005494182,0.000009812089,0.07624538,0.01945257],"study_design_scores_gemma":[0.9135895,0.008790943,0.001034784,0.000161864,0.00575361,0.00001030015,0.0004302665,0.007671444,0.0003718648,0.0001036582,0.06194002,0.0001416835],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9675907,0.0008045755,0.0004821353,0.02085096,0.00436549,0.004163289,0.0007368292,0.00005984211,0.0009462112],"genre_scores_gemma":[0.9824337,0.002450912,0.001390802,0.002976971,0.003945875,0.0003222931,0.0009439206,0.00006423175,0.00547129],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01931089,"threshold_uncertainty_score":0.9999242,"prediction_status":"machine_predicted_unvalidated"},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"agree"},{"id":"W2126372889","doi":"10.1158/1078-0432.ccr-06-2610","title":"Correlation between Development of Rash and Efficacy in Patients Treated with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib in Two Large Phase III Studies","year":2007,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":383,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Rash; Erlotinib; Internal medicine; Medicine; Gefitinib; Gemcitabine; Epidermal growth factor receptor; Erlotinib Hydrochloride; Hazard ratio; Gastroenterology; Oncology; Cancer; Confidence interval","retraction":null,"screen_n_in":null,"score":{"opus":0.1488288453879716,"gpt":0.5328739408514896,"spread":0.3840450954635181,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001897061,0.0001357944,0.0004611663,0.0002186812,0.0001272493,0.000009495476,0.00006045941,0.00006917046,0.00003913179],"category_scores_gemma":[0.0006446711,0.00008062915,0.00003541189,0.0006426091,0.0002956017,0.00007615457,0.00007525795,0.0004719409,0.000003872217],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004023862,"about_ca_system_score_gemma":0.0003953011,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003520887,"about_ca_topic_score_gemma":0.001622036,"domain_scores_codex":[0.9977868,0.0002254348,0.0007676997,0.0003315342,0.0004912722,0.0003972489],"domain_scores_gemma":[0.9975196,0.001537474,0.0001332761,0.0001561693,0.0004968311,0.0001567154],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.002699398,0.001649504,0.9633865,0.00005602279,0.0001645662,0.00001062663,0.002380471,0.000001339138,0.00003655838,0.00001313563,0.0002585328,0.02934329],"study_design_scores_gemma":[0.03854463,0.0009327852,0.9577301,0.000388461,0.00005393369,1.756273e-7,0.0004832623,0.00001039876,0.001146743,0.000003818926,0.0006235939,0.00008208451],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9970117,0.0006252473,0.0000245619,0.0006873345,0.00006389796,0.001469117,0.00004980177,0.00001071404,0.00005759998],"genre_scores_gemma":[0.9991195,0.0001548387,0.0001751977,0.0000538166,0.0001345832,0.00009666938,0.00009649489,0.00001830792,0.0001506115],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03584523,"threshold_uncertainty_score":0.3287961,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null}]}